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Abstract 
Angiogenesis is the formation of new blood vessels from a pre-existing vascular 
network. Angiogenesis is stimulated by proteins called growth factors. Growth 
factors have been used to treat ischemic tissue for some time. When they were first 
used to induce angiogenesis, application of a single growth factor was used; this had 
limited success. Hence, there has been a move towards releasing two or more pro-
angiogenic growth factors to induce blood vessel formation. 
Three growth factors were investigated: vascular endothelial growth factor (VEGF); 
platelet derived growth factor (PDGF); and endothelial growth factor (EGF). These 
growth factors were chosen due to potential for binding and, to a lesser extent, for 
size variation.  
Two sets of materials have been used to study the release of these proteins. The first 
set of materials contained oleyl phenyl hydrogen phosphate (OPHP) to bind to the 
protein. The second was materials containing poly (2-Acrylamido-2-methyl-1-
propane sulfonic acid) (PAMPS) to bind the protein of interest. These systems mimic 
heparin through electrostatically binding to the growth factor peptide sequences 
containing arginine and lysine amino acids. These two systems showed differing 
release profiles for each protein over the course of 31 days.  
OPHP and PAMPS variants containing a fluorescent label were also synthesised. 
Acryloxyethyl thiocarbamoyl rhodamine B was added during polymerisation and 
resulted in materials containing a fluorescent label. However, these showed signs of 
aggregation both during and after synthesis.  
The OPHP materials and PAMPS materials were set into hydrogel sheets composed 
of poly (N-vinyl-2-pyrrolidone-co-diethylene glycol bis allyl carbonate). The release 
of VEGF, PDGF and EGF was studied and exhibited a different release profile than 
OPHP or PAMPS materials.  
Two novel systems have been developed that can successfully bind and release 
various heparin binding proteins by electrostatic binding of the growth factors on 
to or within the outer layer of polymer particles.  It has been concluded that the 
protein size and the shell architecture have the main effect upon the release profile 
of the proteins.   
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 Angiogenesis 
 
Angiogenesis is the formation of new blood vessels by branching from a pre-existing 
vascular network. Angiogenesis mainly occurs during embryogenesis and to some 
extent in adults, such as neovascularisation after wound healing, disease processes 
and in the female reproductive system. It is distinct from vasculogenesis, as 
angiogenesis relies on the migration of endothelial cells and remodelling of 
vasculature, rather than the differentiation of endothelial cells from angioblasts  [1]. 
Both processes consist of similar regulatory mechanisms [2]. The cellular and 
molecular mechanisms of angiogenesis differ depending upon the tissue type, hence, 
the method of stimulating angiogenesis must be adjusted to the target tissue [3]. 
Angiogenesis can be induced by a variety of factors such as, the expression of 
angiopoietins, such as TIE receptors, members of growth factor families; for 
example, the vascular endothelial growth factor (VEGF) family, transforming growth 
factors (TGF), platelet derived growth factors (PDGF) and the fibroblast growth 
factor (FGF) family; along with tumour necrosis factor- α and interleukins [4].  
Normal health and healing requires a balance between angiogenic inhibitors and 
angiogenic stimulators. For the process of angiogenesis to occur a number of 
coordinated events must take place. Angiogenic stimulants are released and diffuse 
across tissues. These bind to nearby pre-existing blood vessels, promoting 
vasodilation. This is followed by endothelial cell basement membrane degradation 
by protease, such as the matrix metalloproteinase (MMP) family, which removes the 
collagen and other extracellular matrix components. This allows the endothelial 
cells to migrate from pre-existing blood vessels to the source of the angiogenic 
stimuli, resulting in cell proliferation and the formation of new vasculature [5]. The 
initial blood vessel sprout begins to arrange into tubes containing a lumen. Lumen 
formation is dependent upon the cell-cell adhesion glycoprotein E-selectin [6]. Once 
these initial blood vessels are in place, remodelling must occur to produce a larger, 
mature vascular network. The crucial step in this is the recruitment of smooth 
muscle cell-like pericytes, which are differentiated from mesenchymal cells, and are 
known to stabilise newly formed vasculature [7].  
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 Wound healing  
 
Wounds are “a defect or a break in the skin, resulting from physical or thermal 
damage or as a result of the presence of an underlying medical or physiological 
condition” [8]. Wounds are categorised into acute or chronic wounds. Acute wounds 
result in minimum scarring and usually heal within 8-12 weeks [9]. Acute wounds 
are normally a result of physical trauma. Chronic wounds are often reoccurring 
wounds that result from underlying medical conditions. Chronic wounds do not heal 
within the normal time frame, i.e. healing time is greater than 12 weeks [9].  
Wound healing is a specific biological process that occurs after injury. The purpose 
of wound healing is to seal the wound quickly to reduce the risk of bacterial 
infection, followed by the regeneration of damaged tissues. There are four main 
stages of wound healing (although these are occasionally described in five stages), 
see Figure 10.1.  
 
Figure 10.1 Schematic of wound healing within the epidermis and dermis of the skin. Image adapted from 
[10]. 
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Haemostasis  
Haemostasis begins with bleeding from the wound. The aim of this process is to 
assist with the flushing out of bacteria, thereby, preventing an infection [11]. 
Fibronectin that is present in wound exudate begins the clotting process by 
promoting the release of clotting factors. This begins with the coagulation of the 
exudate (absence of blood cells or blood platelets). A fibrin network clot follows and 
finally scab formation occurs. This provides strength to the clot and protection from 
infection [8].  The fibrin clot also provides guidance for cell migration and 
proliferation at later stages of healing [12]. Platelet mediated vasoconstriction 
prevents excessive blood loss during scab formation [11]. 
 
Inflammation 
Inflammation often occurs simultaneously with haemostasis, but, in some instances, 
can begin up to 24 hours after injury. Inflammation lasts between 1-3 days and 
involves a cellular and vascular response to the injury. Upon injury, exudate is 
released from the wound. This contains histamine and serotonin which causes 
vasodilation.  The first immune cells to arrive at the site of injury are neutrophils. 
These remove any microorganisms that are present within the wound [11]. Unless 
infection occurs, neutrophils are the predominant immune cell present within the 
first few days after injury [13, 14].  Vasodilation allows phagocytes to enter the 
wound site and remove any potentially necrotic tissue. The clotting process is 
assisted by platelets, which are released from damaged blood vessels, becoming 
activated when in contact with collagen [8]. 
 
Migration and Proliferation 
The aim of the migration and proliferation stages is to restore the wound surface, 
re-vascularise the tissue and structurally repair connective tissue [11]. Migration of 
cells to the wound site is essential for a wound to heal. In initial stages of wound 
healing, fibroblasts and epithelial cells separate themselves from the extracellular 
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matrix (ECM) and migrate to the site of injury. Fibroblasts migrate from the edges 
of the wound underneath the scab followed by epithelial cells that thicken the cell 
layers [8]. As migration across the wound bed occurs, the cells leave markers, 
allowing for ECM production [12].  
Proliferation occurs from 3 days post injury and lasts for 2-3 days. Growth of 
capillaries and lymphatic vessels into the wound site produces granulation tissue. 
Granulation tissue replaces the fibrin/fibronectin matrix [12]. Granulation tissue is 
predominantly fibroblasts, is highly vascular and has a high metabolic rate. This is 
why healing wounds have a pink hue compared to non-injured tissue [11]. Collagen 
is synthesised to provide structure and strength to the tissue. Epithelial thickening 
occurs until collagen has fully filled the wound. High levels of fibroblast proliferation 
and collagen synthesis occurs for approximately 2 weeks. After this, blood vessels 
decrease in size and oedema is reduced [8]. Re-epithelisation has occurred when 
keratinocytes (the main epithelial cell in the skin) have completely covered the 
wound area [11].  
Angiogenesis occurs during this stage. After injury the wound becomes hypoxic and 
the pH drops to 6.8 [11].  The relationship between hypoxia and angiogenesis will 
be discussed in detail later (page 5).  
 
Maturation/ remodelling phase 
Depending upon the type of injury, the maturation phase can last from a few months 
up to 2 years. This phase forms cellular connective tissue and strengthens the 
epithelium. It is in this phase that final scar formation is determined [8, 15]. 
Remodelling involves mainly macrophages and fibroblasts. Wound maturation and 
remodelling is identified by ECM formation/shaping, increased collagen production 
and apoptosis [12]. Although increased strength is a marker that the wound is 
undergoing maturation, the tissue will never gain more than 80% of its original 
strength [16, 17]. 
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1.2.1 Hypoxia, oxidative stress and nitroxidative stress 
The oxygen supply to a wound is determined by a number of factors, such as, 
pulmonic gas exchange, blood vessel density, haemoglobin levels, cardiac output 
and oxygen consumption of inflammatory cells within the wound [18, 19].  Healing 
wounds require a higher oxygen supply than normal tissue due to the increased 
oxygen consumption from proliferating cells, collagen synthesis, immune response 
and the presence of NADPH-linked oxygenase species [19].  
Hypoxia is the reduction of normal oxygen level in tissues. There are three 
categories of hypoxic tissue. Chronic hypoxia is oxygen tension of 2-3%. Under the 
limited oxygen diffusion that occurs with chronic hypoxia, cells begin to 
uncontrollably proliferate [20]. Chronic hypoxia lasts for a relatively long time in 
comparison to other forms of hypoxia.  Due to this, normal cells cannot survive but 
tumour cells with mutations that survive hypoxic conditions are able to proliferate. 
Acute hypoxia and hypoxia with reperfusion can also be described as intermittent 
hypoxia [21]. Even in these short periods of limited oxygen diffusion, irregular and 
new blood vessel growth can still occur. This leads to increased oxygen diffusion at 
that site and also an increase in free radical species leading to tissue damage [21]. 
During hypoxic conditions angiogenesis is regulated by hypoxia-inducible factors 
(HIF) [22]. Immune cells that are present in hypoxic tissue after a wound release a 
series of pro-angiogenic growth factors [23, 24].  
Oxygen can be reduced in one, two or four electron transfers. These produce a 
superoxide (O2•), a peroxide anion (HO2•) and a hydroxyl ion (HO•). O2• and HO2• can 
cause oxidative cell damage if in high enough concentrations [25]. Redox 
homeostasis is the cell’s ability to prevent build-up of excess reactive oxygen species 
[26].  Some reactive oxygen species are important for wound healing as they provide 
protection from microorganisms [27]. However, reactive oxygen species must be 
detoxified or scavenged to prevent damage to the healthy cells.  If these are 
maintained in high concentrations oxidative stress occurs.  
Reactive nitrogen species are also capable of causing cell damage but they play a 
major role in wound healing [28]. NO and peroxynitrite (ONOO•) are the main two 
nitrogen species present. Platelets, macrophages, keratinocytes, endothelial cells 
and fibroblasts are all present in wounds and are capable of producing NO during 
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wound healing [26]. This can lead to the rapid oxidation of NO, also known as 
nitroxidative stress.  
In acute wounds oxidative and nitroxidative stress are not a problem as antioxidant 
defence mechanisms can cope with the gradual detoxification of harmful species. 
This means cells can be returned to redox homeostasis without much trouble [26]. 
However, chronic wounds show uncontrolled production of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS). Therefore, the normal antioxidant 
defence mechanism is not effective [29]. This leads to chronic wounds becoming 
trapped in the inflammatory stages of wound healing meaning no granulation tissue 
can form, finally resulting in long healing times and poor wound closure [26]. 
ROS have been shown to promote angiogenesis by enhancing the affinity of 
fibroblast growth factor-2 (FGF-2) for its receptor (FGFR) and inducing increased 
expression of FGFR. Small quantities of ROS also promote the release of VEGF from 
keratinocytes during wound healing [27]. NO species have a more profound role in 
promoting angiogenesis. It has been shown that NO activates VEGF, basic fibroblast 
growth factor (bFGF) and transforming growth factor β (TGF-β). These promote 
endothelial cell migration and proliferation [26]. 
 
 Growth factors  
 
Growth factors have been used to treat ischemic tissue for some time. It has been 
shown that, during angiogenesis endothelial cells can proliferate and move along a 
chemotactic gradient via ECM tracts towards the source of pro-angiogenic growth 
factors [30-32]. The original course of treatment was bolus injection to the affected 
site. This led to poor results, often due to the short lifetime of growth factors in an 
aqueous environment. Hence, a more localised, controllable delivery system is 
needed.    
There are several pro-angiogenic growth factors that can stimulate endothelial cell 
migration and proliferation. When growth factors were first used to induce 
angiogenesis, application of single growth factors was used [33]. This had limited 
success, with problems including: immature blood vessels[34], leaking of resultant 
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blood vessels[35], impeding lymphatic vessel functionality [36], and incomplete 
angiogenesis [3]. Hence, there has been a move towards releasing two or more pro-
angiogenic growth factors to induce blood vessel formation. The release of several 
growth factors in sequence mimics the release after injury. By using a more natural 
release of protein, the resultant vessels can be shown to be more mature, have 
thicker walls, induce smooth muscle cell migration and have a greater blood vessel 
volume [37].  
 
1.3.1 Vascular Endothelial Growth Factor 
Vascular endothelial growth factor (VEGF) is essential for normal angiogenesis to 
occur. VEGF was discovered in 1989 by Ferrara et al [38]. The protein discovered in 
1989 was found to be the same as that known as Vascular Permeability Factor (VPF), 
which had been discovered by another group in 1983 [39]. VEGF belongs to the 
cysteine knot superfamily and is a dimer consisting of two units of identical 
molecular weights (~23 KDa), giving an approximate molecular weight of 45 KDa 
[7, 40]. Members of the VEGF family of growth factors include: placental growth 
factor (PLGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E.  
VEGF is produced by many different cell types, including tumour cells, osteoblasts, 
keratinocytes, smooth muscle cells and some immune cells, such as macrophages 
and T-cells. VEGF is known to play a major role in the proliferation and migration of 
endothelial cells [41]. This is achieved by interaction through the N-terminal amino 
acid sequence APMAG. As well as interaction with cells, VEGF also stimulates the 
release of vascular permeability factors and hexose transport molecules [42]. 
However, the most essential role of VEGF is as a regulator of pathological 
angiogenesis [43].  
VEGF exists as five different isoforms [7]. These variants of VEGF differ by amino 
acid length. The five isoforms are 121, 145, 165, 189 and 206 amino acids, with 
VEGF121 and VEGF165 being the most abundant within the body [42]. VEGF121 is 
freely available by diffusion, whereas, VEGF165 binds to heparin sulphate and 
becomes associated with extracellular matrix and cell surface proteoglycans [7]. All 
isoforms share a common amino-terminal binding domain which consists of 115 
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residues and is unaffected by the varying length in the carboxy-terminal end. 
Endothelial cells have two VEGF receptors on the cell surface. These receptors are 
VEGFR-1 (Flt-1), a fms-like tyrosine kinase and VEGFR-2 (KDR/Flk-1), a kinase 
domain region [44, 45].       
      
1.3.2 Platelet Derived Growth Factor 
In normal cells, PDGF is at almost undetectable levels and only gets released in 
response to platelet degranulation [30]. PDGF is composed of two homologous 
polypeptide chains: chain A and chain B [46]. Each chain is a similar size and 
conformationally shows no difference in biological activity [30]. The two chains of 
PDGF can assemble into 3 isoforms: AA, BB and AB. The response of each isoform is 
dependent upon what PDGF receptor is available for binding. PDGF receptors are 
composed of two subunits: α and β [47, 48]. Both forms of receptor belong to the 
tyrosine kinase receptor family. They have specificity, with receptor α binding PDGF 
A and PDGF B, while receptor β will only bind PDGF B [30]. The PDGF receptor is 
expressed on the surface of pericytes, smooth muscle cells and capillary endothelial 
cells [46, 49-51]. PDGF plays a role in increasing DNA synthesis, forming angiogenic 
chords and sprouts; and forming mature and stabilised blood vessels [49, 50, 52]. In 
vivo experiments demonstrated that PDGF is crucial in recruiting pericytes to the 
capillaries and thus increases the structural integrity of these vessels [34]. Studies 
have also shown that PDGF may be a source of endothelial cell proliferation by 
upregulating the release of VEGF from smooth muscle cells, thereby indirectly 
affecting the recruitment of endothelial cells [53]. However, it is important to note 
that PDGF is not essential in the early stages of angiogenesis and has a weaker 
angiogenic effect than VEGF [34].  
Endothelial cells grown in culture have been shown to bind PDGF A and B, in 
contrast to isolated endothelial cells which bind significantly less PDGF B. However, 
endothelial cells that are organised into 3D tubular structures, as would be desired 
for tissue engineering purposes, do not bind PDGF B [49, 54].  
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 The role of heparin sulphate family 
 
Heparan sulphates (HS) are a family of glycosaminoglycans (GAGs) produced by 
cells. GAGs are polysaccharides that often contain a net charge. Figure 1.2 shows the 
structure of heparin, which is in the HS family. HS are the most structurally complex 
GAG [55] and are both synthesised as proteoglycans. Heparin is only produced by 
mast cells whereas heparan sulphate is produced by most cells [55]. HS is present 
on cell surfaces and in the ECM. There are several structural differences which have 
been reviewed at length between heparin and HS [55-58]. Only differences directly 
relating to the binding of proteins will be discussed.  
 
Figure 1.2 Structure of heparin. The large quantities of negatively charged groups give an overall net negative 
charge. 
 
 Heparin is a more sulfonated variant of HS. Heparin and HS have an affinity for 
binding to many proteins through non-covalent interactions. There are a variety of 
binding sites along the heparin/HS chain and many variants of heparin-protein 
binding sites [59]. Many proteins that can bind to heparin also show an interaction 
with HS, thereby making the distinction and characterisation of heparin/HS-protein 
binding difficult to determine.  The majority of interactions between heparin/HS-
proteins are ionic interactions [60]. This is due to the number of sulfo and carboxyl 
groups present. Heparin has stronger interactions (2.7 negative charges per 
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disaccharide) compared to HS (<2 negative charges per disaccharide) [59]. Due to 
this, heparin binding sites on proteins are often characterised by groups of 
positively charged basic amino acids. The most common basic amino acids found in 
heparin/HS-protein binding domains are arginine and lysine. They are both 
positively charged at physiological pH, however, arginine can bind approximately 
2.5 times stronger than lysine [61]. Non-electrostatic interactions are also present 
in HS-proteins. Interactions with pro-angiogenic growth factors are reliant on 
electrostatic interactions. These will therefore be discussed in more detail. 
Binding specificity  and affinity is achieved by the orientation and patterning of the 
sulfo and carboxyl groups along the polysaccharide chain [59]. Many HS-protein 
interactions have been studied. It was found that a sequence consisting of [-X-B-B-
X-B-X-] and [-X-B-B-X-X-B-X-] where B is a basic amino acid and X is a hydrophilic 
region shows a strong interaction with ECM [62]. Depending upon the orientation 
of the protein’s secondary structure, it is not necessarily crucial to have a linear 
order of HS binding regions. This means that spatial arrangement can become more 
important than sequential arrangement in HS binding regions [63].  
The binding of VEGF to HS is distinctly different from the VEGFR binding domain. 
The heparin-VEGF interaction is weak when compared to other HS-growth factor 
interactions but is comparable to the binding affinity of HS-PDGF [64]. However, 
unlike VEGF, PDGF bind more strongly through lysine rather than arginine [65]. 
Both VEGF and PDGF can bind to varying length polysaccharides. For both growth 
factors the minimum length chain is an oligosaccharide [66, 67]. It has been shown 
that this HS-VEGF interaction is crucial for the binding of VEGFR by stabilising VEGF 
from becoming inactivated [64]. It is not yet clear if the HS-PDGF interaction plays 
an important role in the binding of PDGFR [67]. 
 
 Treatment with VEGF and PDGF in wound healing 
 
Angiogenesis is essential in wound healing. Without the pro-angiogenic growth 
factors associated with blood vessel growth, wounds could not heal properly. In the 
general population this is not a problem. However, in certain cases this normal 
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healing process does not occur. Two cases will be briefly discussed; impaired 
healing due to diabetes mellitus and after burn injury.  
In diabetic patients the production of VEGF is impaired [68]. It has been shown in 
diabetic mice fibroblasts that the production of VEGF and response to hypoxia are 
diminished compared to wild-type [69]. The inflammatory phase also differs in 
diabetic patients. Chronic moderate inflammation takes the place of the normal 
acute inflammatory phase. This results in a reduced number of macrophages and 
poor lymphatic vessel formation [69, 70]. Long term reduced VEGF production leads 
to impaired angiogenesis and poor formation of granulation tissue, resulting in 
reduced VEGF secretion in wounded tissue [68, 71]. Treatment with VEGF protein 
and VEGF gene-carrying plasmid (phVEGF165) has been shown to slightly reduce the 
need for amputation in diabetic patients with critical limb ischemia [72].  Delivery 
of VEGF-C in a similar manner has shown improvement in angiogenesis and 
lymphomagenesis, resulting in wound closure in diabetic mouse models [73].  
For complete healing of a wound, PDGF is needed to produce mature vasculature. 
During wound healing, PDGF is present in wound fluid. However, in diabetic animals 
the level of PDGF expression is reduced [74]. To improve diabetic wound healing 
PDGF may be used. The use of topical PDGF-BB gels have shown improved soft tissue 
healing in diabetic rats [75, 76]. A similar PDGF-BB gel has been used to show 
healing of full thickness wounds. Healthy volunteers were treated with either a 
conventional antibiotic ointment commonly used on wounds or a PDGF-BB gel. The 
study showed that the PDGF-BB gel improved wound healing faster than 
conventional treatment [77].  
The assessment of the type and severity of a burn is essential to determine the type 
of treatment needed [78]. Full thickness burns take a long time to heal, are at high 
risk of bacterial colonisation and can result in significant skin contraction leading to 
scarring [79, 80]. If the wound is large or the vascular bed is heavily damaged or 
destroyed, re-vascularising the area can be difficult. VEGF has been used to re-
establish a blood supply as a pre-treatment of burn wounds prior to grafting [81, 
82]. The application of VEGF has been shown to reduce dermal necrosis and increase 
microvasculature before grafting [83]. PDGF has been shown to enhance tissue 
repair when applied to skin grafts. PDGF signals through macrophages which are 
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present in wounded tissue. This produces a positive autocrine feedback loop 
resulting in further expression of growth factors needed in wound healing [84]. 
Guinea pig models have shown that multiple applications of PDGF to healing tissue 
can result in faster granulation tissue formation, indirectly resulting in faster healing 
times [85]. 
 
  Release mechanisms 
 
Growth factors can be released via a number of techniques. The most notable of 
these are: directly loading the protein into the polymer matrix; covalently binding 
the growth factors to a peptide sequence; using the polymer to encapsulate the 
growth factors; and the growth factors binding to the polymer via electrostatic 
binding. 
The main problem associated with release of growth factors from polymeric 
matrices or carriers is controlling the release kinetics of the protein. The typical 
burst release profile shows the majority of growth factor being released from the 
polymer within 24 hours of binding. The remainder of the growth factor will be 
released slowly over time. The type of binding and depth of binding can have a 
profound effect on the release profile of the protein from the matrix. In one study, 
pre-encapsulation and deeply embedding the bound growth factors in a polymeric 
matrix led to release being sustained for up to 21 days [86]. There have been efforts 
to control the release kinetics of growth factors from polymers by altering the 
molecular weight, porosity, polymer degradation and erosion, protein diffusion and 
growth factor loading concentrations [87-89]. 
Therapeutic application of pro-angiogenic growth factors can cause problems when 
applied in large doses to a non-localised area. Such problems include the 
development of new blood vessels and increase in vascular permeability in non-
target tissue and tumour growths [90]. Therefore, the direct application of small 
doses of growth factor is preferential and has been shown to yield better results.  
Research into the therapeutic application of VEGF originally used intra-arterial 
bolus injection as the administration technique. To overcome problems associated 
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with non-localised delivery of growth factors, many research groups focus on 
synthetic or natural carriers of growth factors. The aim of this delivery system is to 
provide a small, consistent dose of growth factors, minimise side effects associated 
with application to non-target tissues and maintain the bioactivity of the protein to 
prolong the half-life of the growth factors [91-93].  
As with all biomaterials, the delivery system for pro-angiogenic growth must be 
non-immunogenic, must not degrade to give toxic by-products and must be easily 
sterilised. It is also advantageous for the material to be easy to handle and be 
relatively simple and cheap to produce, as these are requirements for clinical 
application and commercialisation [91]. There have been many different materials 
and approaches investigated for the release of one or more growth factors and this 
area has been extensively reviewed [37, 94-96]. Figure 1.3 shows a schematic of the 
four main ways growth factors have been released. 
 
 
 
Figure 1.3 The four main ways in which proteins may be bound to a polymer surface. A) use of carrier system, 
B) directly loading onto the polymer surface, C) electrostatically binding the protein to the polymer and D) 
covalent bonds to the polymer backbone. 
A 
B
  A 
C
  A 
D
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1.6.1 Direct Loading 
The most simplified way to incorporate growth factors into a polymer is to directly 
load the protein into the material. This process is diffusion controlled, hence, the 
release profile of the growth factor is not consistent. It will show an initial burst 
release phase followed by a slow release of a small amount of protein that has 
become incorporated deeper in the polymeric matrix. Cross-linking of the polymer 
can be utilised to modify the release profile of growth factors and proteins that have 
been incorporated via direct loading [97]. However, the use of cross-linking can 
affect the efficiency of the protein release. If growth factors are added to the polymer 
prior to cross-linking, the growth factors may not still be functional after the 
polymer has been cross-linked. The distribution of protein evenly throughout the 
material cannot be ensured if growth factors are added after cross-linking [97].  
 
1.6.2 Covalently binding 
It is also possible to synthesise polymers with the ability to covalently bind to the 
amino acid sequence of growth factors, effectively tethering the amino acid 
sequence to the polymer [97]. Using these tethers, there is the potential to spatially 
arrange the growth factors within or on the surface of the polymer.  The tethers can 
be made up of peptide sequences, synthetic polymers, natural polymers and whole 
proteins [98-100]. Along with allowing for growth factor release, growth factors 
covalently bound to a polymer surface by tethers can also increase cell adhesion, cell 
migration and extracellular matrix (ECM) production on the surface of the polymer 
[101-103]. Poly (ethylene glycol) (PEG) tethers have been used to bind VEGF and 
TGF-β1 to the surface of a polymeric growth factor carrier. PEG was used to tether 
cell adhesive peptide sequence RGD to the surface of a matrix metalloproteinase 
sensitive hydrogel [104]. This system allowed for VEGF to be retained on the 
polymer and only released upon cell demand. Alternatively, growth factors can be 
immobilised on the surface of a polymer using a 15-amino acid tag containing free 
sulfhydryl groups for specific conjugation to VEGF [99]. 
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1.6.3 Carrier systems 
Using a carrier system, such as drug release implants and microparticles, can reduce 
the rate of growth factor release over a longer period of time [97]. This technique 
has advantages when multiple growth factors are being applied as it allows for 
temporal and spatial arrangement of proteins within the polymer [94]. The growth 
factors of interest can either be spread throughout the polymer matrix or in the 
centre surrounded by a polymeric barrier to diffusion. Both of these techniques not 
only slow the release of growth factor to cells but also protect the delicate proteins 
from the biological environment [105, 106]. There are two main release systems 
that can be utilised in the release of growth factors from polymeric carrier systems: 
non degradable systems and degradable systems.  
Non-degradable systems consist of an insoluble polymer matrix which contains the 
protein of interest. The movement of the growth factor out of the polymer is driven 
by concentration gradients and is only rate limited by mass transport. The polymer 
can be tuned to alter the release rate to give zero or first order release kinetics [106, 
107].  
Degradable systems have attracted great interest due to the number of degradable 
polymers with excellent biocompatibility. Along with diffusion of the growth factor 
out of the polymer, degradable systems can also be synthesised so the degradation 
of the polymer plays a major role in the release rate of the growth factors. This is of 
particular advantage in cases where more than one protein is released from the 
polymer. By tuning the release rate, each growth factor can have different release 
kinetics, depending upon the needs of the biological system [37, 106, 108].  
 
1.6.4 Electrostatic interactions 
Both VEGF and PDGF can bind to heparan sulphate whilst biologically active within 
the body [109]. This interaction can be utilised to prevent protein denaturing when 
the growth factor is bound to the polymeric matrix of the scaffold. Heparin binding 
domains are able to interact with the cell surface to promote adhesion of cells. 
However, their role of interest is their ability to bind to growth factors. Utilising HS 
binding domains can be used as a mechanism for controlled, precise release of 
growth factors in vivo [110, 111]. It is possible to include heparin-binding peptides 
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into a synthetic or natural hydrogel to promote adhesion of cells to the surface of 
the hydrogel and release growth factors [112-115]. The heparin spacer mimics the 
ECM, protecting the growth factor and spatially arranging the protein release from 
within the scaffold [98].  
Heparin-growth factor binding occurs through a series of highly basic peptide 
sequences containing arginine and lysine amino acids. This makes it possible to use 
basic functional groups on the surface of the polymer to bind VEGF [116]. The use 
of specific groups to target electrostatic binding to VEGF and PDGF will be discussed 
later.  
 
 Materials overview 
 
Although there are a wide array of signalling molecules important in the angiogenic 
response of endothelial cells, much of the research has been undertaken into 
controlled release of VEGF. The different materials and binding mechanisms have 
had varying success. However, a clear pattern can be seen when looking at release 
profiles. The first is a burst release phase, usually between 1-12 hours. This often 
follows with a region of slow release, eventually plateauing to a region in which little 
to no growth factor is released. Table 1-1 is an overview of the different materials 
that have previously been investigated.  
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Material Author Year 
Polyethylene glycol (PEG) diacrylate hydrogel[117] P.A. Netti 2012 
Trimethylene carbonate, e-caprolactone and D,L 
lactide[118] 
B.G. Amsden 2012 
Polylactic-co-glycolic acid (PLGA) and PLGA 
polymer[119] 
A.L. Daugherty 2011 
Dextran (DEX) and poly(lactide-co-glycolide) 
(PLG)[120] 
X. Jia 2011 
Poly(lactic-co-glycolic acid) (PLGA)[121] O. Karal-Yilmaz 2011 
Poly(ether)urethane polydimethylsiloxane 
blend[122] 
E. Briganti 2010 
Polystyrene-co-divinyl benzene core oleyl phenyl 
hydrogen phosphate-co-ethylene glycol 
dimethacrylate  shell[116] 
L. Gilmore 2009 
Alginate[93] S.M. Jay 2009 
Amino acid ester polyphosphazene (Pphos)[123] O. Oredein-McCoy 2009 
Gelatin[124] Z. S. Patel 2008 
Poly(DL-lactic) acid (PLA)[125] J. M. Kanczler 2007 
Poly(lactide-co-glycolide) (PLG)[86] A.B.Ennett 2006 
Poly (D,L-lactide-co-glycolide)[126] J. Davda 2005 
Poly(D,L-lactide-co-glycolide)[127] A.Z. Faranesh 2004 
Table 1-1 Brief overview of polymer materials used for release of VEGF since 2004. 
 
Soon after researchers began looking at the effect that VEGF had on endothelial cells 
it became apparent that single growth factor release was not sufficient to produce 
useful vasculature. The focus shifted to looking at release of other pro-angiogenic 
growth factors. PDGF is important for stabilising angiogenic sprouts and forming 
strong vessels that are not prone to leaking. As with VEGF binding, a burst release 
phase is seen, followed by slow PDGF release. Table 1-2 is an overview of the 
materials used to bind and release PDGF.  
  
 
 
18 
 
Material Author Year 
Hydroxyapatite, PLGA 
microspheres[128] 
J.J. Delgado 2012 
Cellulose acetate[129] J.E. Tengood 2011 
Alginate and poly lactide-co-
glycolide (PLG)[130] 
Q. H. Sun 2010 
Polyurethane[131] B. Li 2009 
Kapp-carrageenan[132] V.E. Santo 2009 
poly(lactic-co-glycolic acid) 
(PLGA50) and 
poly(L-lactic acid) (PLLA) [133] 
G.B. Wei 2006 
Methylidene malonate[134] L. Desire 2006 
poly(epsilon-caprolactone)[135] 
(PCL)-chitosan 
S.Y. Im 2003 
Chrondroitin-4-sulfate (CS)-
chitosan[136] 
Y.J. Park 2000 
Ethylene vinyl acetate 
copolymer (EVAc)[137] 
W.R. Walsh 1995 
Table 1-2 Overview of natural materials used for the release of PDGF. 
 
 Determining bio-activity of proteins 
 
In vivo and in vitro assays are used to test the bioactivity of a biological molecule or 
drug. The use of bio-assays has been developed over many years and there are 
several commonly used experimental protocols that have been developed to assess 
the ability of a material or substance to promote angiogenesis [138-141]. Due to the 
large variety of assays available only a very brief summary will be included. 
 
1.8.1 In vitro angiogenesis assays 
 In vitro assays are used to mimic the physiological environment but do not use 
living animals. In the case of angiogenesis assays, these are mostly focused on the 
use of endothelial cells. Only the most commonly used assays will be discussed in 
this thesis.   
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Endothelial cell proliferation assay 
One of the markers of angiogenesis is the proliferation of endothelial cells. By 
quantifying this proliferation and the use of suitable controls, the ability of a 
substance to induce or inhibit angiogenesis can be determined. The presence of 
increased proliferation demonstrates that the molecule of choice (for example, 
growth factors or drugs) can bind to the cell receptors and induce a biological 
response. As with most cell culture based assays, a combination of detection 
methods is best. To determine the degree of endothelial cell proliferation MTT assay, 
DNA synthesis and DNA binding combined with flow cytometry have been used 
[139, 142-144]. 
 
Endothelial cell migration assay 
Endothelial cell migration assays are one of the most commonly used in vitro 
angiogenesis assays. There are a variety of different techniques and different 
materials used for determining the migration of endothelial cells. The first is a 
transfilter based assay. This uses a modified Boyden chamber that allows cells to 
migrate through pores in the upper chamber along a chemotactic gradient present 
due to a pro-angiogenic source in the bottom chamber [145]. This technique has 
been of particular use in the study of tumour formation [146]. The phagokinetic 
track method is a high throughput technique for determining cell movement by 
looking at the movement of the overall population of cells. From there, it is possible 
to work backwards and determine the type of movement of individual cells. 
Although this technique is not only used for angiogenesis assays, it has been shown 
to be of use when determining the migration of endothelial cells [140, 147]. Finally, 
fibrin or collagen coated wells and Matrigel have been used to show endothelial cell 
migration [148, 149]. These mimic the ECM, as such, endothelial cells can move 
towards the source of pro-angiogenic factors. The use of Matrigel will be discussed 
further in following sections.  
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Endothelial cell differentiation assays 
Endothelial cell differentiation assays are mainly focused on tubule formation. In 
angiogenesis, tubules are formed after proliferation and migration and just prior to 
lumen formation. Tubule formation assays are often performed in a 3D matrix such 
as ECM components, Matrigel or reduced growth factor Matrigel [139, 150, 151]. 
The use of Martigel must be undertaken with caution as it has been shown to induce 
tubule formation in non-lumen forming cells [148]. The degree of angiogenesis is 
assessed by measuring the average tubule length, the number of tubules formed, the 
average tubule area and the number of branching points [148]. Endothelial cell 
differentiation assays can be modified to include co-culture with different cell types. 
 
Endothelial cell co-culture 
Many different cell types play a role in angiogenesis and the influence of these 
varying cell types on endothelial cells is complex. Endothelial cell co-culture is useful 
for giving a more realistic physiological environment. Co-culture assays often look 
for the same angiogenic markers as described previously, but with the advantage of 
being able to study the interactions between different cell types. Various cytokines 
[152-154], the influence of adhesion molecules [155] and interactions with  
mesenchymal stem cells (MSCs) [156] have been studied. As with previously 
discussed assays, there are several different matrices in which to grow cells.  Again, 
Matrigel is often the matrix of choice and is well studied. However, caution must be 
exercised, especially when working with non-lumen forming cell types [148]. 
 
Organ culture 
Organ culture can bridge the gap between in vitro and in vivo experimentation. 
Whole sections of tissue are cultured and the micro vessel outgrowth is monitored 
[139].  Organ culture is the least used in vitro technique due to the technical 
difficulties and relatively high cost in comparison to other in vitro methods. The 
three most understood organ culture methods are the porcine carotid artery model 
[157], the aortic ring model [158-160] and the vena-cava aorta model [161].  
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1.8.2 In vivo angiogenesis assays 
 In vivo assays are performed in an animal model. By using a whole animal the 
immune response and inflammatory response can be studied along with the pro 
or anti angiogenic response of the material under investigation. The main in vivo 
angiogenesis assays will be looked at in greater detail.  
 
Chick chorioallantoic membrane (CAM) assay 
The chorioallantoic membrane (CAM) is a vascular membrane found in eggs and 
is formed by the chorion and allantois fusing during development. The CAM is 
analogous to the placenta in mammalian development. At this early stage in 
development the chick is relatively immunotollerant so can be used for studying 
cross species xenografts [139]. To perform a CAM assay the shell must be cut 
away. It is important to remove all shell dust as any remaining dust can lead to 
an inflammatory response [139]. Through this window in the shell, the materials 
of interest can be applied directly to the surface of the CAM [162, 163], implanted 
underneath the CAM or injected intravenously [164, 165]. Due to the flexibility 
and potential to test several materials using a single animal, the CAM assay is a 
popular choice for in vivo study.   
 
Material implantation assay/ hindlimb ischemia model 
It is possible to implant a material that can induce angiogenesis into a whole animal 
model. This is referred to as a hindlimb ischemia (HI) model.   The HI model is used 
to investigate neovascularisation and angiogenesis in mice or rabbits.  To begin with, 
ischemia must be induced by ligating the femoral artery in the hindlimb. Ischemia 
must be confirmed using laser Doppler imaging [166]. After ischemia has been 
induced, the material of interest can be implanted or injected subcutaneously. The 
restoration of blood perfusion and blood vessel outgrowth are measured. The HI 
model is widely used because it allows for study of the immune response to a 
material and the effect of hypoxia on the rate of angiogenesis. The HI model allows 
for injection of peptides and other angiogenic binders [167, 168], various polymer 
materials [169-172] and for cell and gene therapy [173-175]. 
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Corneal angiogenesis assay 
The corneal angiogenesis assay monitors vascular development in the cornea. The 
cornea is an avascular area so any vessel growth can be attributed to the material or 
pro-angiogenic factors under investigation. The assay is done by cutting a small 
pocket in the cornea. The material of interest can then be inserted.  The material 
inserted includes polymers [176], pro-angiogenic factors [177] and stem cells [178]. 
The newly formed vasculature can be determined by measuring vessel penetration 
into the cornea and by using fluorescent dyes or ink to visualise the new blood 
vessels [139, 179].  
 
Dorsal air sac model 
The dorsal air sac model uses repeated subcutaneous injections of air resulting in 
the formation of an air pouch [180, 181]. After several days of repeated injection, 
the cells of the air pouch become translucent and the formation of new vessels on 
this surface can be studied [182].  The material of interest can then be implanted 
into this cavity. The vessel growth towards the implant can be monitored. This can 
be done by the injection of Evans Blue which will leak from newly formed vessels 
but does not leak from pre-existing vasculature [139]. 
 
Zebrafish angiogenesis assay 
Zebrafish are used as a whole animal model for the study of blood vessel growth 
[183]. Despite being a non-mammalian species, zebrafish organs are a close match 
to humans [184]. They are a good candidate for laboratory experimentation as they 
can be housed in large numbers, have a relatively short generation time and are 
developed externally (within an egg sac). Their young are transparent allowing 
internal development to be viewed with a microscope and they can be genetically 
manipulated [185]. Zebrafish embryos have the ability to survive severe 
cardiovascular defects, allowing for study and manipulation of the developing 
vascular system [186, 187]. 
 
 
23 
 
Transgenic zebrafish lines marked with green fluorescent protein (GFP) on their 
endothelial cells allow for the real time development of vasculature to be studied 
[188, 189]. Along with GFP transgenic fish, other fluorescent markers can be used 
to visualise how different cell types interact. An example of this is the double 
transgenic line Fli-eGFP GATA dsRED where the endothelial cells are green and red 
blood cells are red. This allows for vascular development and blood flow to be 
visualised [139].  
Zebrafish have been used for fundamental understanding of vascular development 
for many years. More recently, zebrafish have been used to study the promotion or 
inhibition of angiogenesis. Zebrafish have been used as high throughput screening 
agents by the addition of pro- and anti-angiogenic molecules to their culture media 
[190, 191]. Microinjection techniques allow for controlled release systems to be 
tested using zebrafish models.  These techniques are usually undertaken at the 
embryonic or larval stages of development. There have been several studies using 
microinjection of loaded micro or nano-particles into zebrafish to test the release 
profile, bioactivity and cytotoxicity of the payload [192-194]. 
 
 Emulsion polymerisation 
 
Particle systems are popular in the field of medical research and biomaterials. 
Reasons for this include: large surface area, ability to adsorb small molecules onto 
the surface or encapsulated within them, and the high mobility which particles have 
due to their small size. Polymer colloids for binding biological molecules can be 
synthesised in one of two ways. The first is a two-step process in which the desired 
polymer is first synthesised, followed by the formation of particles. The more 
favourable technique is the use of emulsion polymerisation to produce the polymer 
of the desired particle size in one step [195].  
Emulsion polymerisation is a process in which radical chain polymerisation occurs 
in the form of a colloidal dispersion. This is distinct from suspension or dispersion 
polymerisation due to the size of  the droplets, the type of initiation used and the 
resultant polymer (otherwise known as a latex) molecular weight and reaction 
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parameters [196]. Emulsion polymerisation holds some distinct advantages over 
other polymerisation techniques. Firstly, the colloidal system allows for easy control 
of the thermal and viscoelastic problems that are associated with bulk 
polymerisations. Secondly, the latex produced by emulsion polymerisation does not 
regularly need further separations. Finally, the kinetics of emulsion polymerisations 
allows the polymer molecular weight to be increased without decreasing the 
polymerisation rate. Emulsion polymerisation can produce latexes with high 
molecular weight and high reaction rates [196]. The size of latex particles can range 
between 50-300 nm.  
Emulsion polymerisations are composed of monomer(s), a dispersal medium 
(usually water), surfactant and a water-soluble initiator. To maintain the colloidal 
dispersion, the emulsion system is kept well agitated (usually by stirring) 
throughout the polymerisation. Surfactants contain both hydrophobic and 
hydrophilic sections and when the concentration of surfactant exceeds the critical 
micelle concentration (CMC) the surfactants aggregate together to form micelles. 
This transforms the polymerisation mixture into a colloidal system. The free energy 
of the system is reduced by the formation of micelles and the surface tension also 
decreases. Micelles formed are typically 2-10 nm, however, by increasing the 
amount of surfactant, a larger number of smaller micelles can be formed [196]. By 
using a mixture of surfactants it is possible to control the size, and number of 
micelles, along with size of the resultant latex particles [197].  Water insoluble 
monomers are used for emulsion polymerisations. The majority of the monomer is 
located in large (1-100 µm) monomer droplets. The size of these droplets is 
controlled by the stirring rate of the reaction. However, a small proportion of 
monomer is located within micelles. These micelles containing monomer have a 
surface area more than two orders of magnitude bigger than monomer droplets. The 
micelles act as an inbetween point for the water-soluble initiator and the 
hydrophobic monomer. It is within the micelles that polymerisation occurs. As 
polymerisation occurs, monomer concentrations are replenished by the release of 
monomer from monomer droplets into the aqueous phase. There is some debate as 
to the mechanism by which initiation occurs in emulsion polymerisation. The first 
suggested mechanism for the formation of polymer particles is by micellar particle 
nucleation. This is when radicals (primary or oligomeric) from the aqueous phase 
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enter the micelles [198, 199]. This mechanism has suggested that it is the dominant 
nucleation process when the surfactant concentration is well above the CMC. At, or 
below the CMC, it has been suggested that homogenous nucleation plays a minor, 
but significant, role in the formation of polymer particles. The homogenous particle 
nucleation mechanism involves radicals polymerising in solution to give oligomeric 
radical species. These then become insoluble and precipitate out of the aqueous 
phase. This precipitate is stabilised by the surfactant present in the aqueous phase, 
allowing absorption of monomer into the droplet [196].  
 
 Phosphate functionalised core-shell particles 
 
Core shell particles can be used to control the properties of a material. The outer 
shell and inner core can be synthesised with different properties and functionalities 
to alter how the material interacts and degrades [200]. Core-shell particles have 
many uses, including, surface coatings, printing, catalysts, sensors, biomedical 
applications and drug delivery [201]. Core-shell particles are usually spherical with 
the core and shell made from different materials.  Crosslinking density can be 
altered to change the particle morphology and to change the properties of the 
material [202]. Core-shell particles can be classified as hydrogel-like or non-
hydrogel-like. Hydrogel-like particles have a water swollen shell surrounding a 
collapsed hydrophobic core. Alternatively, both the core and shell can be hydrogels 
[203]. Hydrogel-like particles are formed with pores or holes throughout the 
structure. The density of porosity, size of pores and pore interconnection can be 
determined by the crosslinking density and the composition of the monomers used 
for polymerisation [204]. 
Core-shell particles are usually produced in a multi-step process. The core is first 
synthesised, followed by addition of the shell [205-207]. Multi-step syntheses can 
be time consuming and costly to produce on large scales. Single step methods can 
also be used to produce core shell particles.  
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There are three standard methods for producing core-shell polymer particles: 
dispersion, precipitation and emulsion polymerisations [208-210]. These are shown 
in Figure 1.4. Emulsion polymerisation is the most commercially viable process to 
produce core-shell particles. Industrially, a semi-batch emulsion process is used. 
However, in academic research batch emulsions are favoured due to the 
simplification of reaction kinetics and the possibility of avoiding problems 
associated with using large reactors [211, 212].   
 
Figure 1.4 (A) Synthesis of core-shell particles in a two-step process. This can be done via emulsion, 
dispersion or precipitation.  (B) Core-shell particle synthesis using a reactive surface. (C) Step wise coagulation 
of smaller particles on to larger particles followed by heat treatment can also produce core-shell particles. (D) 
Core-shell particle formation using block copolymers. 
 
 
Core-shell polymer latexes consisting of a poly(styrene-co-divinyl benzene) core 
and oleyl phenyl hydrogen phosphate (OPHP) shell have been used to study the 
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release of vascular endothelial growth factor [213]. The study was based on 
molecularly imprinted particles to bind and release VEGF over time. Molecularly 
imprinted particles have been shown by Carter et al. [214-216] to recognise 
molecules through hydrogen bonding and electrostatic interaction of the phosphate 
group along with hydrophobic interactions. Short peptide sequences were used in 
an epitope approach to selectively bind to VEGF. However, the study showed that 
the performance was not markedly better than the non-imprinted poly (styrene-co-
divinyl benzene) core OPHP shell latexes. This led to the conclusion that it was the 
electrostatic binding of the phosphate groups to VEGF that allowed for release. This 
mimics the binding of growth factors to heparin. The net negatively charged heparin 
can bind to VEGF via its basic peptide sequence containing arginine and lysine amino 
acids. 
OPHP was originally synthesised by Takagi et. Al. in 1996 [217]. The position of the 
double bond on the long alkyl chain means that OPHP is relatively unreactive. Rather 
than copolymerising into the particle shell, OPHP is incorporated by radical transfer 
via hydrogen abstraction [216]. The same basic latex constituents were maintained 
but the ratio of ethylene glycol dimethacrylate (EGDMA) crosslinker was varied to 
change the properties of the particle shell. The decrease in crosslinker changes the 
openness of the particle, producing a material that can bind VEGF deep within the 
shell. An increase in crosslinker produces a shell with a higher barrier to diffusion, 
meaning any VEGF that is within the shell will take longer to diffuse out. The 
addition of glycerol methacrylate acetonide (GMAC) produced an open particle shell 
allowing VEGF to bind deeper within the shell. The ratios of EGDMA and GMAC 
crosslinkers can be altered to produce a size exclusion effect as well as 
electrostatically binding to VEGF, PDGF and EGF.  
 
 
 Poly (2-acrylamido-2-methyl-1-propane sulfonic acid) stabilised particles 
 
Poly (2-acrylamindo-2-methyl-1-propane sulfonic acid) (PAMPS) was used as a 
negatively charged polymer shell for binding of VEGF, PDGF and EGF.  Previous work 
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by Liekens et al. and García-Fernández et al. put forward the hypothesis that PAMPS 
acts as an anti-angiogenic unit when in culture with human umbilical vein 
endothelial cells (HUVECs) [218, 219]. It was concluded that this was due to pro-
angiogenic growth factors binding to the sulfonic acid units on the PAMPS chains. 
This led to cell death as the cell became starved of nutrients as the PAMPS removed 
growth factors from solution.  
PAMPS was synthesised via reversible addition-fragmentation chain-transfer 
polymerisation (RAFT).  RAFT was first reported in 1998 and showed that 
controlled molecular weights, with narrow polydispersities could be achieved using 
a  wide range of monomers and reaction conditions [220]. The synthesis of polymers 
using a RAFT agent or chain transfer agent (CTA) allows synthesis with control over 
molecular weight. A typical RAFT polymerisation reaction contains the following 
units: initiator, monomer, chain transfer agent (RAFT agent), and solvent. The 
termination steps have been removed resulting in the polymer chains growing at a 
constant rate until very high monomer conversion. The mechanism of RAFT 
polymerisation involves a reversible addition fragmentation sequence in which 
transfer of the S=C(Z)S- moiety between active and dormant chains serves to 
maintain the continuous character of the polymerisation. The RAFT agent can be 
varied, giving functionality to the capping group at the chain end. A variety of 
capping molecules can be used. This gives control of the polymer end groups 
allowing for a variety of different polymer architectures.  
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Figure 1.5 Generalised mechanism of RAFT polymerisation. In stages 1 -2 of the polymerisation the reagents 
[S=C(Z)S-R] are rapidly transformed into a polymeric thiocarbonylthio [S=C(Z)S-Pn] by reaction with 
propagating radical (Pn.). In stages 3 and 4, the radical liberated (R.) reacts with a monomer to form a new 
propagating radical (Pm.). Chain extension of the polymeric thiocarbonylthio compound [S=C(Z)S-Pm] occurs. 
The reversible addition-fragmentation sequence in which the S=C(Z)S- moiety is transferred between dormant 
and active chains maintains the living character of the polymerisation.  Termination occurs when Pn and Pm 
radicals combine 
 
RAFT polymerisation methods have been used for many years to provide polymers 
with a variety of end groups. The RAFT agent 4-vinylbenzyl-pyrrole carbodithioate 
(4-(VPC)) has been used to synthesise branched poly(2-Acrylamido-2-methyl-1-
propane sulfonic acid) (PAMPS) [221]. The linear equivalent of 4-(VPC) has been 
used to produce linear poly (2-Acrylamido-2-methyl-1-propane sulfonic acid) 
(PAMPS). 
 
1 
2 
3 
4 
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Figure 1.6  (A) Reaction scheme of the synthesis of branching RAFT agent 4-vinylbenzyl-pyrrole 
carbodithioate, 4-(VPC) (B) Reaction scheme of synthesis of branching RAFT agent 4-benzyl-pyrrole 
carbodithioate. 
The presence or absence of a vinyl group on the RAFT agent allows for synthesis of 
branched or linear polymers. Branched polymers can contain more functionality in 
comparison to linear polymers, but they have a broad molecular weight distribution 
and can have irregular branching and distribution of functionality [222].  
The linear and branched polymers synthesised by RAFT can be thought of as macro-
RAFT agents. Using them as such, allows for further polymerisations. RAFT has been 
used in emulsion polymerisations to produce polymer particles with controlled 
molecular weights [223, 224]. The behaviour, including kinetics of RAFT agents in 
emulsion polymerisations is similar to that in homogeneous polymerisation [196]. 
A 
B 
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Macro-RAFT agents have also been used as stabilisers in surfactant-free emulsion 
polymerisation. Surfactant-free emulsion polymerisations have some advantages 
over traditional emulsion reactions. These include, eliminating the need to remove 
surfactant after synthesis and allowing for a better understanding of how different 
monomers behave in emulsion polymerisations [225]. Trithiocarbonate and 
dithiocarbonate based RAFT agents have been used to form macro-RAFT agents 
capable of producing block copolymer structures that rearrange to form core-shell 
particles [226-229]. Hydrophobic units organise themselves in the centre of the 
particle with hydrophilic (often charged) units acting as stabilisers by organising 
themselves around the outside. Due to this behaviour, a surfactant is no longer 
needed to stabilise the water immiscible monomer.  
Linear PAMPS (L-PAMPS) and branched PAMPS (B-PAMPS) were used as macro-
RAFT agents in the emulsion polymerisation of n-butyl methacrylate (BMA). This 
produced core-shell particles with a poly (butyl methacrylate) (PBMA) core and 
PAMPS shell. The sulfonic acid group gives the particles a net negative charge within 
the shell. This can mimic a net negative charge similar to heparin. Since VEGF and 
PDGF are both heparin binding pro-angiogenic growth factors, the PAMPS shell can 
be used as a heparin mimic for the stabilisation and release of VEGF and PDGF. The 
design of the shell produces a material that can bind different sized growth factors 
with a size exclusion effect. The L-PAMPS produces an open flexible shell. The B-
PAMPS produces a mesh which can exclude molecules larger than the mesh size. The 
release profile of the smaller protein EGF was also investigated to confirm the size 
exclusion hypothesis.  
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Figure 1.7 Hydrophobic PBMA core surrounded by a negatively charged hydrophilic PAMPS shell. Either L-
PAMPS or B-PAMPS is added to stabilise the synthesis of PBMA. 
 
 Fluorescent labelling of core-shell particles 
 
Fluorescently labelled materials can have a variety of applications, including: 
material tracking during in vitro and in vivo experiments; diagnostics; and imaging 
[230]. Small polymer particles are often labelled with a variety of fluorescent units 
for studying cell uptake and tracking with tissues [231].  There are a variety of 
factors that influence the cellular uptake of a polymer particle. The particle size and 
morphology dictate if the particle will be taken in by cells. Generally, the particle 
must be between 50-200 nm in diameter [232]. Finally, the use of a transfection 
agent in the form of an amphiphilic polymer also affect the uptake of polymer 
particles [232]. 
Rhodamine B is a fluorescent dye with an emission maximum at 570 nm which is 
often used in cell biology, histology or as a biochemical reagent [231]. Acrylated 
Particle core 
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forms of rhodamine B are commercially available and allow for incorporation of the 
fluorescent dye to polymers.   
It is possible to use batch emulsion polymerisations to produce particles 
incorporating the fluorescent dye [233]. It is known that the addition of a 
fluorescent label can inhibit free radical emulsion polymerisation [234], therefore, 
inclusion of a dye is usually kept at 1 mol % [231]. The particles discussed in section 
1.10 (page 25) and 1.11 (page 27) were synthesised with the fluorescent label 
acryloxyethyl thiocarbamoyl rhodamine B. 1:1 OPHP:EGDMA particles and 2:1:1 
OPHP:GMAC:EGDMA particles were synthesised by a two-step emulsion process. 
This allowed the acryloxyethyl thiocarbamoyl rhodamine B to be contained within 
the particles core. L-PAMPS and B-PAMPS particles were synthesised in a one-step 
process, therefore the label was dispersed throughout the particle. Both methods 
produced pink latexes. Initial problems with particle aggregation got worse upon 
standing, finally resulting in an unstable and relatively unusable latex. 
 
 Hydrogels with embedded core-shell particles 
 
Hydrogels are highly water swollen polymer networks. They are a popular choice of 
material for medical devices, cell scaffolds, wound dressing and drug delivery 
vehicles due to their similar mechanical properties to natural tissue. Hydrogels are 
easy to functionalise and can be synthesised to respond to a stimulus [8, 235-239].  
Synthetic hydrogels are easier to maintain consistency over processing of natural 
tissue when produced in large quantities [240]. 
The term wound dressing covers everything from cotton bandages to new synthetic 
wound care systems that can promote healing by maintaining a constant 
environment and delivering drugs or anti-microbials [239]. Since wound care can 
be very varied there are many different types of wound dressing on the market, each 
tailored towards a particular type of wound. However, there are some common 
features that most wounds need for healing. These include: a warm moist 
environment, unimpeded epithelial cell movement, efficient oxygen circulation and 
protection from bacterial colonisation[8].  When choosing or designing a wound 
dressing the following must be taken into consideration. First, the wound must be 
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cleaned (debridement) to remove any necrotic tissue or bacteria. Hydrogels are 
unique compared with other wound dressings as they promote autolytic 
debridement [241]. The wound must be placed in a moist environment to prevent 
any further cell death, promote cell replication and enhance angiogenesis. Any 
excess exudate or blood must be removed as this can prevent new tissue formation. 
The gaseous exchange needs of the wound must be examined. Lower oxygen levels 
promote angiogenesis while higher oxygen levels stimulate growth of fibroblasts 
and epithelial cells. To promote dermal recovery the blood supply must be 
stimulated by maintaining the wound at body temperature. Finally, the dressing 
must have low adherence to the wound to prevent further trauma, must be cost 
effective and not need to be changed frequently [8].  
Hydrogels can be tailored to suit all of these environments and therefore are a 
commonly used material for wound dressing. However, these types of dressing can 
occasionally need a second covering, such a gauze, or a semi-permeable polymer 
backing to allow gaseous exchange and prevent the gel from drying out [8]. Due to 
the high water content, hydrogels have been shown to have a cooling effect and have 
previously been used to reduce patient pain when treating chronic leg ulcers [242]. 
Hydrogels are suitable for wounds in each of the stages of wound healing, although 
they are not suitable for wounds that are extremely infected or are producing a lot 
of exudate [243].  
Using hydrogels as a medium for inducing angiogenesis is the obvious choice. This 
is because hydrogels can incorporate biological molecules or drugs to promote 
angiogenesis whilst being a good candidate for a wound dressing. As previously 
discussed, there are many different growth factors that can be used to assist with 
angiogenesis and promote wound healing. Rather than discussing the particular 
proteins released, only the method of release will be discussed.  
Ionic gelatin hydrogels have shown positive results of sustained protein release 
using cell culture and murine hind limb ischemia models [244]. Poly(ethylene 
glycol) diacrylate (PEGDA) hydrogels have generally low protein adsorption 
properties. However, various biological molecules and proteins can then be 
immobilised onto the surface of the hydrogel using covalent linking units [102, 245]. 
Injectable alginate gels blended with VEGF have been shown to be a potential easy 
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to administer pro-angiogenic material. Alginate gels containing VEGF were cooled 
forming a liquid. Upon warming up after injection they formed a solid gel that could 
administer VEGF and produce and angiogenic response in murine ischemic 
hindlimb models [246]. Natural molecules, such as heparin, incorporated into 
hydrogels have also shown some promising results. Poly(hyaluronan-co-PEGDA) 
gels can bind thiol modified heparin via the hyaluronan units in the hydrogel. This 
has been shown to induce angiogenesis in murine models [247]. Work by Gilmore 
et. al. used poly(n-vinyl-2-pyrrolidone-co-diethylene glycol bis-allyl carbonate-co-
acrylic acid) hydrogels functionalised with peptides, RRR and KKK, followed by 
heparin to bind VEGF [248]. This showed low cytotoxicity and good ability to 
promote proliferation in human dermal microvascular endothelial cells (HUDMEC) 
on the surface of the hydrogel.  
Poly(N-vinyl-2-pyrrolidone) (PVP) has commonly been used as a constituent in 
medical devices. This is because PVP is water soluble, biocompatible, has excellent 
haemocompatability and extremely low cytotoxicity [249]. PVP is crosslinked with 
flexible units to overcome the poor mechanical properties of PVP [250, 251]. Several 
different synthesis techniques have been used to produce PVP containing gels. 
These include: UV curing [252], electrospinning [253], and various radiation 
techniques [254-258]. Depending upon the use of the dressing it is possible to pre-
cure the hydrogel or cure the gel in situ.  
 
 Alternative protein analysis techniques 
 
Enzyme linked immunosorbant assays are often used to detect protein released 
from polymers. ELISA is an extremely sensitive technique that is commonly used in 
research and medical diagnostics. However, it is not without faults. Denatured or 
partially degraded protein is not always detected via ELISA and cross reactivity of 
various proteins can cause problems when analysing in-pure samples. This can give 
both false positive and false negative results. This is especially true when dealing 
with proteins where there is not a general agreement on the degradation products. 
Also, due to their sensitivity and use of anti-bodies, ELISA is can be an expensive 
analytical technique.  
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Other methods can be used to identify and quantify proteins present in a solution. 
Gel electrophoresis and mass spectrometry are two analytical techniques that are 
often used in protein synthesis. More recently they have been used in combination 
with antibodies to develop mass spectrometry based immunoassay diagnostic 
techniques [259]. The sensitivity is high and the techniques for protein detection are 
well established. Soft ionisation techniques such as MALDI and ESI are used to 
identify proteins. When dealing with unknown proteins, mass spectrometry is often 
coupled with gel electrophoresis then peptide sequence fingerprints can be 
compared to a database of other known proteins of similar origin [260]. 
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2 Project Aims and Objectives 
The aim of this project was to produce a system of delivering growth factors. The 
project was focused on the promotion of angiogenesis for increasing the healing 
time of chronic wound. Finding a delivery system that can promote angiogenesis 
successfully would have impacts in a variety of medical fields.  
The project was designed to produce materials that are versatile, easy and cheap to 
produce delivery system. Scalable emulsion reactions were used to produce 
particles that can be tuned in size by varying the crosslinker. A negatively charged 
outer shell has been used rather than more traditional methods for binding growth 
factors. This was chosen because it can be synthesised on a larger scale compared 
to other methods and the charged groups can be easily incorporated into the 
polymer during a batch emulsion process.  
The specific objectives where: 
 Expand upon previous work based on OPHP functionalised core-shell 
particles. This will be done by increasing the number of monomers included 
in the particle shell and by expanding the range of proteins under 
investigation.  
 Investigate the protein binding ability of PAMPS coated particles. Determine 
the effect of shell architecture using linear and branched PAMPS shell 
particles.  
 Set particles into hydrogels to produce a wound dressing like system. This 
will also allow for direct comparison of the performance of materials studied 
with heparin functionalised hydrogels.  
 Investigate the possibility of alternative protein detection techniques, such 
as mass spectroscopy and gel electrophoresis.  
It was expected that the negative charge on the surface of the various core-shell 
particles would bind and release pro-angiogenic proteins over time. In this case the 
particles would be acting as a HS mimic. The quantity and availability of the particle 
charge and shell architecture was expected to have effects on the material 
performance.   
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3 Materials and Methods 
 Synthesis of OPHP functionalised core-shell particles 
 
OPHP functionalised core-shell particles were made via a two-step batch emulsion 
process.  
3.1.1 Synthesis of oleyl phenyl hydrogen phosphate (OPHP) 
Synthesis of OPHP has previously been described by Gilmore [91, 116]. The 
synthesis below has been replicated from her PhD thesis.   
 
Figure 3.1 Structure of oleyl phenyl hydrogel phosphate 
Oleyl alcohol (65.5g, Sigma Aldrich) was added drop wise over 30 minutes to stirring 
phenyl phosphodichloridate (50g, Sigma Aldrich). The mixture was stirred for 60 
minutes at room temperature. The temperature was increased to 50oC and the 
reaction was stirred for 16 hours. The solution was added drop wise over 1 hour to 
rapidly stirring ice cold water (300ml). The reaction was left for 1 hour and then 
extracted into diethyl ether (3x100ml, Fisher). The organic extracts were dried with 
magnesium sulphate, followed by filtering and rotary evaporation. The resultant 
product was a brown oil. The product was purified on a silica column using a 
gradient from 90:10 DCM: methanol. Molecular formula: C22H37O4P (mass 396) % 
yield: 56.5 % Analysis was completed via elemental analysis (Expected: C 67.9%, H 
9.73%. Analysis: C 67.27%, H 9.93%), 1H NMR ((CDCl3, 250MHz) δH (ppm): 0.87 (t, 
3H, CH3), 1.26 (m, 22H, -CH2-), 1.62 (dt, 2H, - CH2CH2-OP), 2.00 (dt, 4H, -CH2CH=), 
4.05 (d, 2H, -CH2OP), 5.38 (dt, 2H, -CH=CH-), 7.10-7.32 (m, 5H, -C6H5-), 8.88 (s, 1H, 
OH)), 31P NMR(CDCl3, 162MHz) δP (ppm): -4.0228) and mass spectrometry MH+ : 
425. 
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3.1.2 Synthesis of glycerol methacrylate acetonide (GMAC) 
GMAC was routinely synthesised using the following protocol.  
 
Figure 3.2 Structure of glycerol methacrylate acetonide. 
Methacrylic anhydride (94.2g, Sigma Aldrich) was added drop wise to dry solketal 
(66.08g, Sigma Aldrich), pyridine (63.28g, Sigma Aldrich) and DCM (500ml, dry from 
Grubbs system) under nitrogen at 0oC. The solution was stirred at room 
temperature for 24 hours followed by the addition of water (250cm3, 18.2 MΩ cm at 
25oC, Millipore, UK). The organic phase was washed with water and solvent 
removed by rotary evaporation. 
Amberlite IRA 402 was washed with 1M NaOH for 2 hours then washed with water 
followed by acetone. The crude GMAC was added and gently shaken overnight. The 
product was filtered and distilled under reduced pressure. Molecular formula: 
C10H16O4 (mass: 200) % yield: 62.0 %. 1H NMR (dDMSO): δ= 1.40 (s, O(O)C-CH3), 
1.85 (s, CH3-C=CH2), 3.75 (ddd, CH-CH2-O), 3.83 (ddd, CH-CH2-O), 4.05 (ddd, O-CH2-
CH), 4.20 (ddd, O-CH2-CH), 4.95 (m, CH(H)=CH3),  5.65 (d, CH(H)=CH2).  
3.1.3 Synthesis of poly (styrene-co-divinyl benzene) core 
 
Figure 3.3 Structure of poly (styrene-co-divinyl benzene) produced by emulsion polymerisation. 
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Styrene (Sigma Aldrich) and divinyl benzene (Sigma Aldrich) were distilled before 
use.  
A jacketed reaction vessel was heated to 70oC then purged with N2. A solution of 
MES buffer (0.533g, Sigma Aldrich) in ultrapure water (45ml, 18.2 MΩ cm at 25oC, 
Millipore, UK) was purged with nitrogen for 5 minutes while stirring until solids 
were dissolved. Sodium dodecyl sulphate surfactant (1g, Alpha Aesar) and 
potassium carbonate (0.25g, Sigma Aldrich) were added and stirred until dissolved. 
The solution was sonicated for 10 minutes and adjusted to pH6 through the addition 
of NaOH. The buffer solution was added to the emulsion rig, purged with N2 and 
stirred at 400rpm. Styrene (0.043 moles) and divinyl benzene (0.004 moles) purged 
with nitrogen was added over 30 minutes to stirring solution of buffer. Potassium 
persulphate (0.16g, Sigma Aldrich) dissolved in ultrapure water (7.5ml, 18.2 MΩ cm 
at 25oC, Millipore, UK) was purged with nitrogen for 15 minutes and added to the 
monomer dispersion in a one shot initiation. Polymerisation took place overnight. If 
needed, the reaction was ceased by turning the heat off and sample store at room 
temperature in water. 
3.1.4 Synthesis of poly (oleyl phenyl hydrogen phosphate-co-ethylene glycol 
dimethacrylate) shell 
The quantity of OPHP and EGDMA were varied in each latex to determine the 
importance of the availability of the phosphate for binding protein and the effect of 
crosslinker. The quantities of OPHP and EGDMA used can be found in Table 3-1. 
Ethylene glycol dimethacrylate (Sigma Aldrich) and oleyl phenyl hydrogen 
phosphate were combined with ultrapure water (13.5ml, 18.2 MΩ cm at 25oC, 
Millipore, UK). The solution was purged with nitrogen for 5 minutes then added 
drop wise over 15 minutes to the PS-co-DVB core. The reaction was allowed to 
equilibrate for 1 hour. The initiator solution of potassium persulphate (Sigma 
Aldrich) in ultrapure water (8ml, 18.2 MΩ cm at 25oC, Millipore, UK) was purged 
with nitrogen for 15 minutes, then added to the reaction in a one shot initiation. The 
reaction was stirred at 400rpm and at 70oC overnight. The reaction was ceased by 
turning the heat off and sample store at room temperature in water. 
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Formulation OPHP 
(moles) 
EGDMA 
(moles) 
Potassium 
Persulfate 
(moles) 
 
1:3 OPHP:EGDMA 
 
 
2.5 x 10-3 
 
9.6 x 10-3 
 
1.2 x 10-3 
 
1:1 OPHP:EGDMA 
 
 
5.0 x 10-3 
 
4.8 x 10-3 
 
1.2 x 10-3 
 
3:1 OPHP:EGDMA 
 
 
10.0 x 10-3 
 
2.4 x 10-3 
 
1.2 x 10-3 
Table 3-1 Formulation for poly (oleyl phenyl hydrogen phosphate-co-ethylene glycol dimethacrylate) shell. 
 
3.1.5 Synthesis of poly (oleyl phenyl hydrogen phosphate-co-ethylene glycol 
dimethacrylate-co-glycerol methacrylate acetonide) shell 
The quantity of EDGMA and glycerol methacrylate acetonide were varied in each 
latex to determine the effect of crosslinker. The quantities of OPHP, EGDMA and 
GMAC used can be found in Table 3-2. 
Glycerol methacrylate acetonide, ethylene glycol dimethacrylate (Sigma Aldrich) 
and oleyl phenyl hydrogen phosphate were combined with ultrapure water (13.5ml, 
18.2 MΩ cm at 25oC, Millipore, UK). The solution was purged with nitrogen for 5 
minutes then added drop wise over 15 minutes to the PS-co-DVB core. The reaction 
was allowed to equilibrate for 1 hour. The initiator solution of potassium 
persulphate (Sigma Aldrich) in ultrapure water (8ml, 18.2 MΩ cm at 25oC, Millipore, 
UK) was purged with nitrogen for 15 minutes and then added to the reaction in a 
one shot initiation. The reaction was stirred at 400rpm and at 70oC for 2 hours. After 
2 hours the temperature was increased to 80oC for 1 hour. The reaction was ceased 
by turning the heat off and sample store at room temperature in water. 
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Formulation OPHP 
(moles) 
EGDMA 
(moles) 
GMAC 
(moles) 
Potassium 
Persulfate 
(moles) 
 
4:1:3 
OPHP: 
GMAC:EGDMA 
 
 
5.0 x 10-3 
 
7.1 x 10-4 
 
4.3 x 10-4 
 
6.3 x 10-4 
 
2:1:1 
OPHP: 
GMAC:EGDMA 
 
 
5.0 x 10-3 
 
5.7 x 10-4 
 
5.7 x 10-4 
 
4.2 x 10-4 
 
4:3:1 
OPHP: 
GMAC:EGDMA 
 
 
5.0 x 10-3 
 
4.3 x 10-4 
 
7.1 x 10-4 
 
6.3 x 10-4 
Table 3-2 Formulation for poly (oleyl phenyl hydrogen phosphate-co-ethylene glycol dimethacrylate-co-
glycerol methacrylate acetonide) shell. 
 
 Synthesis of PVP-co-DEGBAC hydrogels with embedded core-shell particles 
 
N-vinyl-2-pyrrolidone (Sigma Aldrich, UK) and acrylic acid (Sigma Aldrich, UK) were 
distilled under reduced pressure prior to use. Latex particles were washed and 
stored in propan-2-ol. Diethylene glycol bis-allyl carbonate (DEGBAC, Sigma Aldrich, 
UK), glycerol (Sigma Aldrich, UK), azobisisobutyronitrile (AIBN, Sigma Aldrich, UK) 
and hydroxyl-2-methylpropiophenone (2HMPP, Sigma Aldrich, UK) were used as 
supplied.  
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Figure 3.4 Monomers N-vinyl-2-pyrrolidone (NVP) and diethylene glycol bis-allyl carbonate (DEGBAC) that 
are the main constituents of the hydrogels produced. The synthesis was carried out with either thermal or UV 
curing. 
 
3.2.1 Thermally cured hydrogels 
Each monomer and initiator was weighed out according to Table 3-3. Propan-2-ol 
(Sigma Aldrich, UK) containing each latex was added. The solution was stirred under 
nitrogen for 30 minutes. The monomer mixture was injected in between glass plates 
containing a PTFE gasket. The hydrogel was thermally cured for 18 hours at 70oC. 
After curing the glass plates and PTFE gasket was carefully removed and hydrogel 
stored under propan-2-ol. 
Particle NVP 
(moles) 
DEGBAC 
(moles) 
Latex 
(g) 
IPA 
(moles) 
AIBN 
(moles) 
Glycerol 
(moles) 
Control (PVP-co-
DEGBAC) 
3.6 x 10-2 6.6 x 10-4 - - 3.7 x 10-4 - 
B PAMPS 3.6 x 10-2 6.6 x 10-4 1.2 - 3.7 x 10-4 - 
L PAMPS 3.6 x 10-2 6.6 x 10-4 1.4 - 3.7 x 10-4 - 
OPHP 3.6 x 10-2 6.6 x 10-4 1.4 - 3.7 x 10-4 7.6 x 10-3 
GMAC 3.6 x 10-2 6.6 x 10-4 1.4 - 3.7 x 10-4 7.6 x 10-3 
Table 3-3 Quantities used for thermally cured synthesis of PVP-co-DEGBAC hydrogels containing embedded 
latex particle. 
3.2.2 UV cured hydrogels 
Each monomer and initiator was weighed out according to Table 3-4. Propan-2-ol 
(Sigma Aldrich, UK) containing each latex was added. The solution was stirred under 
nitrogen for 30 minutes. The monomer mixture was injected in between quartz 
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plates containing a PTFE gasket. The hydrogel was UV cured for a total of 9 minutes, 
turning over after each minute. After curing the quartz plates and PTFE gasket was 
carefully removed and hydrogel stored under propan-2-ol. 
 
Table 3-4 Quantities used for UV cured synthesis of PVP-co-DEGBAC hydrogels containing embedded latex 
particles. 
 
 Synthesis of acryloxyethyl thiocarbamoyl rhodamine B labelled particles 
 
The emulsion reactor was protected from light throughout the synthesis. 
Styrene (Sigma Aldrich, UK) and divinyl benzene (Sigma Aldrich, UK) and butyl 
methacrylate (Sigma Aldrich, UK) were distilled before use.  
3.3.1 OPHP functionalised particles 
3.3.1.1 Synthesis of poly (styrene-co-divinyl benzene) core containing acryloxyethyl 
thiocarbamoyl rhodamine B 
The emulsion rig was heated to 70 oC then purged with N2. A solution of MES buffer 
(0.533 g, Sigma Aldrich, UK) in deionised water (45 ml, 18.2 MΩ cm at 25oC, 
Millipore, UK)) as purged with nitrogen for 5 minutes while stirring until solids were 
dissolved. Sodium dodecyl sulphate surfactant (1 g, Alpha Aesar, UK) and potassium 
carbonate (0.25 g, Sigma Aldrich, UK) were added and stirred until dissolved. The 
solution was sonicated for 10 minutes and adjusted to pH6 through the addition of 
NaOH. The buffer solution was added to the emulsion rig along with acryloxyethyl 
thiocarbomyl rhodamine B (4mg, Polysciences Inc. Germany) then purged with N2 
and stirred at 400rpm. Styrene (4.3x10-2 moles) and divinyl benzene (3.8x10-3 
moles) purged with nitrogen was added over 30 minutes to the stirring buffer 
Particle NVP 
(moles) 
DEGBAC 
(moles) 
Latex 
(g) 
IPA 
(moles) 
2HMPP 
(g) 
Glycerol 
(moles) 
Control (PVP-co-
DEGBAC) 
8.6 x 10-2 1.7 x 10-3 - 4.0 x 10-2 6.1 x 10-4 - 
B PAMPS 6.8 x 10-2 1.7 x 10-3 1.6 1.3 x 10-2 6.1 x 10-4 - 
L PAMPS 6.8 x 10-2 1.7 x 10-3 1.6 1.3 x 10-2 6.1 x 10-4 - 
OPHP 6.8 x 10-2 1.7 x 10-3 1.1 2.2 x 10-2 6.1 x 10-4 7.6 x 10-3 
GMAC 6.8 x 10-2 1.7 x 10-3 1.1 2.2 x 10-2 6.1 x 10-4 7.6 x 10-3 
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solution. Potassium persulfate (5.9x10-4 moles, Sigma Aldrich) dissolved in 
ultrapure water (7.5 ml, 18.2 MΩ cm at 25 oC, Millipore, UK) was purged with 
nitrogen for 15 minutes and added to the monomer solution in a one shot initiation. 
Polymerisation took place overnight. 
3.3.1.2 Synthesis of 1:1 OPHP: EGDMA shell  
Ethylene glycol dimethacrylate (4.8x10-3 moles, Sigma Aldrich, UK) and oleyl phenyl 
hydrogen phosphate (5.0x10-3 moles) were combined with ultrapure water (13.5 
ml, 18.2 MΩ cm at 25oC, Millipore, UK). The solution was purged with nitrogen for 5 
minutes then added drop wise over 15 minutes to the PS-co-DVB core. The reaction 
was allowed to equilibrate for 1 hour. The initiator solution of potassium persulfate 
(1.2x10-3 moles, Sigma Aldrich, UK) in ultrapure water (8 ml, 18.2 MΩ cm at 25 oC, 
Millipore, UK) was purged with N2 for 15 minutes, then added to the reaction in a 
one shot initiation. The reaction was stirred at 400 rpm and 70 oC overnight. After 
reaction was complete, the heat was turned off. Sample wound be stored in a sealed 
container, protected from light at 4oC.  
3.3.1.3 Synthesis of 2:1:1 OPHP:EGDMA:GMAC shell 
Glycerol methacrylate acetonide (5.7x10-4 moles) ethylene glycol dimethacrylate 
(5.7x10-4 moles, Sigma Aldrich, UK) and oleyl phenyl hydrogen phosphate (5.0x10-3 
moles) were combined with ultrapure water (13.5 ml, 18.2 MΩ cm at 25oC, Millipore, 
UK). The solution was purged with nitrogen for 5 minutes then added drop wise 
over 15 minutes to the PS-co-DVB core. The reaction was allowed to equilibrate for 
1 hour. The initiator solution of potassium persulfate (4.2x10-4 moles, Sigma Aldrich, 
UK) in ultrapure water (8 ml, 18.2 MΩ cm at 25oC, Millipore, UK) was purged with 
N2 for 15 minutes, then added to the reaction in a one shot initiation. The reaction 
was stirred at 400 rpm and 70oC for 2 hours. The temperature was increased to 80oC 
for 1 hour. After reaction was complete, the heat was turned off. Sample wound be 
stored in a sealed container, protected from light at 4oC.  
3.3.2 PAMPS functionalised particles 
Linear or branched PAMPS (0.83 g) and acryloxyethyl thiocarbomyl rhodamine B 
(14.8 mg, Polysciences Inc., Germany) was dissolved in ultrapure water (72 ml, 18.2 
MΩ cm at 25 oC, Millipore, UK).  This was added to the emulsion reactor, purged with 
nitrogen and heated to 60 oC. Butyl methacrylate (0.1 moles, Sigma Aldrich, UK) was 
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added and stirred at 400rpm for 30 minutes.  Potassium persulfate (7.4x10-4 moles, 
Sigma Aldrich, UK) was dissolved in ultrapure water (10 ml, 18.2 MΩ cm at 25 oC, 
Millipore, UK) and added in a one shot initiation. The reaction ran for 8 hours. After 
reaction was complete, the heat was turned off. Sample wound be stored in a sealed 
container, protected from light at 4oC.  
 
 Core-shell particle dialysis and analysis 
 
3.4.1 Dialysis and sterile dialysis of samples 
12-14kDa MWCO dialysis tubing (Spectrum Laboratories Inc.) was soaked in 
ultrapure water (18.2 MΩ cm at 25oC, Millipore, UK). Excess water was tapped off 
and each tube was filled with latex. Dialysis solution of ultrapure water (500ml, 18.2 
MΩ cm at 25oC , Millipore, UK), phosphoric acid (4.9g, Sigma Aldrich, UK) and 
sodium dodecyl sulphate (0.12 g ,2.5% by volume) was prepared. The dialysis 
solution was changed twice daily for 3 days. The dialysis solution was changed to 
ultrapure water (500ml, 18.2 MΩ cm at 25oC, Millipore, UK) and changed twice daily 
for 3 days. After removal from dialysis tubing, samples covered and stored at room 
temperature. 
3.4.2 Deprotection of GMAC units 
 
Figure 3.5 Deprotection of GMAC by removal of acetone group. 
GMAC was deprotected by the addition of 1M HCl (1:4 by volume latex: HCl). This 
was heated in a water bath at 60oC for 5 hours. 
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3.4.3 Particle size analysis 
10µl solution of each latex sample in 25 cm3 10mM KCl was prepared. Particle size 
measurements were taken at 25oC using ZetaPALS zeta potential analyser 
(Brookhaven Instruments Corporation). 
3.4.4 Zeta potential measurements 
10µl solution of each latex sample in 25 cm3 1mM KCl was prepared. References 
were taken for 1mM KCl solution, 10 mM KCl solution and B1-ZR3 reference 
solution. Zeta potential measurements were taken at 25oC using ZetaPALS zeta 
potential analyser (Brookhaven Instruments Corporation). 
3.4.5 Solid content analysis 
0.5ml latex was weighed then dried in a vacuum oven for 48 hours. The sample was 
then weighed again and mass lost and solid content determined. All samples were 
taken in triplicate.  
Solid Content (%) = (mass dry latex (g)/mass wet latex (g))x100 
Material Expected Mass Recovery (%) 
1:3 OPHP:EGDMA 11.30 
1:1 OPHP:EGDMA 9.92 
3:1 OPHP:EGDMA 13.46 
4:1:3 OPHP:GMAC:EGDMA 7.62 
2:1:1 OPHP:GMAC:EGDMA 7.69 
4:3:1 OPHP:GMAC:EGDMA 7.77 
Table 3-5 Expected mass recovery of PS-co-DVB core OPHP:EGDMA shell and PS-co-DVB core 
OPHP:GMAC:EGDMA shell particles. 
 
3.4.6 Transmission electron microscopy 
TEM was carried out using an FEI Tecnai Spirit Microscope operating at 100kV. 50µl 
of 10:1 water to diluted latex were loaded onto gold mesh sample mounts. The 
sample was left for 60 seconds then the water was removed. Samples were stained 
with uranyl formate solution and fully air dried before imaging.  
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 Hydrogel analysis 
 
3.5.1 Water content analysis 
Water content was determined by cutting and weighing small portions of each water 
swollen hydrogel in triplicate. These were then dried in a vacuum oven until 
constant weight. The water content was determined by the following: 
Water content (%) = ((Wwet – WDry)/Wwet) x 100 
3.5.2 Residual monomer content 
Residual monomer content was determined by gas chromatography. Controls of 
NVP and DEGBAC were ran prior to hydrogel samples so peak identity could be 
determined more easily. A Perkin Elmer Autosystem XL with a Phenomenex ZB-5 
column was used throughout. Table 3-6 shows the parameters used for analysis.  
Perkin Elmer Autosystem XL Operating Parameters 
Temperature range 40oC -250oC (temp ramp of 10oC/min) 
Injection temperature 250oC 
Carrier system Helium 
Flow rate 0.8ml/min 
Injection system Autosampler 
Table 3-6 Gas chromatography operating conditions for determining residual monomer concentration. 
 
3.5.3 Scanning electron microscopy 
Polymer samples were dried using ethanol (50%-100% in steps) followed by 
hexamethyldsilazane (50%-10% in steps). Samples were transferred into 100% 
hexamethyldsilazane for 30 minutes followed by air drying the samples overnight. 
Samples were mounted onto aluminium pin-stubs with Leit-C carbon tabs and 
sputter coated (Edwards S150B) with gold. Samples were imaged using a Philips XL 
20 microscope using associated software.  
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 Cell studies 
 
3.6.1 Normal human dermal fibroblast cell culture 
NHDF were cultured in T75 cell culture flask (Corning Life Sciences, USA) with 20 
ml Dulbeco’s Modified Eagle Medium (DMEM, Life Technologies, UK) containing 
10% FBS (Sigma Aldrich, UK) at 37oC with 5% CO2. The media was changed every 3-
4 days and passage occurred once per week when the cells were at 70-90% 
confluence. To passage the media was removed and 5 ml trypsin (Life Technologies, 
UK) was added to each flask. The trypsin was left on cells for approximately 5 
minutes with gentle agitation. The process was monitored using a light microscope. 
10 ml media was added to neutralise the trypsin. The cells were centrifuged to form 
a cell pellet and re-suspended in 10 ml media. Each flask was split into four. 
3.6.2 Endocytosis study 
Tissue culture plastic coated flat bottom 24 well plates (Corning Costar, USA) were 
used for cell culture. Initial studies used 100,000 cells per well. Half were cultured 
for 48 hours until 70-80% confluent and half were seeded and left for 3-4 hours to 
adhere to the surface of the well plate. Cells were cultured at 37oC with 5% CO2. Each 
well contained 1.5 ml DMEM containing 10% FBS. The media was changed for media 
containing sterile rhodamine B labelled particles suspended in PBS. Table 3-7 
contains the volume of particles and volume of media used in each well. The 
particle/media solution was left on the cells for 24 hours. The solution was removed 
and each well was wash 3 times with PBS. Cells were imaged using a fluorescent 
microscope in PBS and disposed of after imaging. 
Particle Concentration Volume of Rhodamine B 
Labelled Particles in PBS 
(µl) 
Volume of DMEM (10% 
FBS) (µl) 
High 500 1000 
Medium 250 1250 
Low 50 1450 
Very Low 25 1475 
Table 3-7 Volume of rhodamine B labelled particles used for cell culture experiments. All particles were 
sterilised and suspended in sterile PBS with a consistent solid content of 10%. 
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 The cell seeding number was also altered. 20000, 40000, 70000 or 100000 cells 
were seeded into a 24 well plate. The cell culture condition were the same as stated 
above. Cells were left for 3-4 hours to adhere to the surface of the well plate and 
either medium or low volume of particles (Table 3-7) were added to each well. Cells 
were cultured for one data point then washed once with PBS and imaged using a 
fluorescent microscope. 
Finally, 40000 cells were seeded onto each well of a 24 well plate, and cultured as 
stated above. A medium volume (Table 3-7) of particles were added and cells were 
cultured for 24 hours. Each well was washed once with PBS and imaged using a 
phase contrast microscope. A positive control of particles with no cells and a 
negative control of cells with no particles was used. Each experiment was carried 
out in triplicate.  
 
 Protein studies  
 
3.7.1 Protein binding and release from particles 
0.5ml phosphate buffered saline (PBS) was added to 0.5ml latex. The samples were 
agitated for 30 minutes then centrifuged until a solid polymer pellet had formed. 
The supernatant was removed leaving the solid polymer. 0.5ml PBS was added to 
the latex solid and agitated for 30 minutes. The sample was centrifuged at 13,000 
rpm for 30 minutes and the supernatant removed. This process was continued until 
the supernatant was pH 7. A solution of 100ng/ml VEGF165/PDGF-BB/EGF 
(Peprotech) solution was made up with the inclusion of 1% bovine serum albumin 
(Sigma Aldrich). 1 ml of this solution was added to each of the polymer samples and 
left at 4oC for 18 hours with gentle agitation. The VEGF165/PDGF-BB/EGF solution 
was removed and replaced with 1 ml PBS. Initial particle protein loading readings 
were taken by removing the supernatant after binding and analysing via ELISA. The 
samples were stored at 37oC for the remainder of the experiment. Supernatant 
samples were initially taken at 1, 2, 6, 12, 24, 48 and 72 hours. This was later 
extended to 96, 120, 144, and 168 hours and finally extended up to 31 days. Samples 
were stored at -80oC until analysis. 
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3.7.2 Protein binding and release from hydrogels 
Each gel was cut into small circles using a cork borer. These were soaked in PBS with 
the solvent changed twice daily for 5 days. The PBS was removed and replaced with 
a solution of 100 ng/ml VEGF/PDGF/EGF in PBS containing 0.1 % BSA. This was left 
at 4oC for 16 hours to bind to the hydrogel. The protein containing solution was 
removed and replaced with PBS containing 0.1 % BSA. The samples were stored at 
37oC for the release time period. Samples were taken at the following time points: 0, 
1, 6, 12, 24, 48, 72 hours. Binding and release experiments were done in triplicate. 
Released samples were stored at -80oC until analysis.  
3.7.3 Protein interactions with heparin 
A solution of 200ng/ml VEGF165 (Peprotech) solution was made up in water with 
the inclusion of 0.1% bovine serum albumin (Sigma Aldrich) and 10% heparin 
(Sigma Aldrich). Samples were heated at 37oC for 24 hours then stored at -80oC until 
analysis.  
3.7.4 Enzyme linked immunosorbant assay protocol 
Either a sandwich ELISA kit from R&D Systems or a sandwich ELISA kit purchased 
from Peprotech were used for analysis. Each kit was utilised following the 
manufacturer’s instructions. The standard protocol for ELISA is as follows (see kits 
instructions for quantities and timings): 
If needed, prepare 96 well plate for by adding capture antibody to each well. 
Incubate then aspirate each well with wash buffer. Wash each well 4 times. Ensure 
sufficient washing by blotting the plate on a paper towel after each washing step. 
Add blocking buffer and incubate. Finish plate preparation by washing each well 4 
times with wash buffer.  
Standard protein calibration was produced by reconstituting protein standard and 
producing a serial dilution from 1000 pg/ml to 0 pg/ml. If needed, a higher 
concentration of standard protein could be used with Peprotech ELISA kits. Each 
standard was analysed in triplicate. If stated, assay diluent was added to each well, 
followed by sample or standard solution. The plate was then incubated at room 
temperature. After the incubation period the plate was washed and aspirated 4 
times.  
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Detection antibody was added to each well. The plate was incubated at room 
temperature then washed 4 times with wash buffer. Peprotech plates then required 
addition of avidin-HRP conjugate and ABTS substrate as separate steps, whereas, 
R&D Systems plates added these together.  After colour had developed, a stop 
solution was used to prevent further colour development. 
The developed plate was read using MRX II plate reader (Dynex Technologies) with 
wavelengths and correction wavelengths as stated by the manufacturer. All samples 
and standards were analysed in triplicate. 
3.7.5 Mass spectrometry 
Samples were prepared as described in section 3.7.1-3.7.3. After collection, samples 
were flash frozen and stored at -80oC until analysis. When needed, samples were 
quickly defrosted. Analysis was ran on using ESI on a waters LTC mass spectrometer 
with TOF analysis.  
3.7.6 Gel electrophoresis 
Mini-Protean TGX pre-cast electrophoresis gels (Bio-Rad, UK) were loaded into a 
Mini-Protean tetra cell tank (Bio-Rad, UK). TGS buffer (Bio-Rad, UK) was diluted to 
1x concentration and added to the tank. For each well 20µl of protein was diluted 
with 20µl Laemmli sample buffer (Sigma Aldrich) and loaded into an 
electrophoresis gel well. All protein samples were ran in triplicate. 10µl protein 
standard (precision plus protein dual colour standard, Bio-Rad) was added to at 
least three wells on each gel. 300V was applied for 5 minutes then 180V for 
approximately 25 minutes. The movement of the coloured standard wells was 
monitored for progression down the gel. The gels were removed from their cases 
and a scalpel was used to remove the top wells. 
3.7.6.1 Staining 
Staining was done using Bio-Rad silver stain plus kit. All glassware was acid washed 
prior to being used with staining solutions. All volumes given are for staining two 
mini gels. All solvent and reagents not supplied in the staining kit were from Sigma 
Aldrich. 
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Reagent Volume (ml) 
Methanol 200 
Acetic Acid 40 
Fixative Enhancer Concentrate 40 
Distilled Water 120 
Table 3-8 Fixative step for 2 mini electrophoresis gels. Fixative enhancer concentrate was supplied in Bio-Rad 
silver stain plus kit. 
Table 3-8 shows the solution used for fixing electrophoresis gels before staining. The 
gels were placed in the solution and left with gentle agitation for 20 minutes. The 
gels were rinsed and washed with 400ml distilled water for 10 minutes. The wash 
solution was decanted off and replaced with a further 400ml distilled water for 10 
minutes.  
Reagent Volume (ml) 
Distilled water 35 
Silver Complex Solution 5 
Reduction Moderator Solution 5 
Image Development Reagent 5 
Development Accelerator Solution 50 
Table 3-9 Staining and development step for 2 mini electrophoresis gels. All solutions were supplied in Bio-
Rad silver stain plus kit. 
The staining and development solution was stirred prior to use. The development 
accelerator solution was added just prior to adding solution to the gel. The 
electrophoresis gels were stained for approximately 20 minutes with gentle 
agitation. When staining was complete, it was stopped using 5% acetic acid solution.  
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4 Results 
 Analysis of OPHP functionalised core-shell particles 
 
Particles were designed with a functional phosphate unit polymerised into the outer 
shell of a PS-co-DVB core particle. The shell was altered by varying the ratio of cross 
linker (EGDMA) and by the inclusion of GMAC, which is assumed to produces a large 
open shell on the particles.  
After dialysis, to remove surfactant, the particle size, zeta potential and solid content 
of the latexes were determined as shown in Figure 4.1. All latexes were stable, with 
a negative surface charge and within the expected size range [196]. The solid 
content measurements for OPHP:EGDMA particles are consistent with normal 
emulsion polymerisation.  
Figure 4.1 shows that as the ratio of OPHP:EGDMA changes there is an effect on the 
particle size. As the ratio of OPHP:EGDMA increases, particle size also increases. The 
less OPHP and more EGDMA the smaller the particle. In this case, EGDMA is a 
crosslinker and an increase in crosslinker quantity leads to a more tightly porous 
structure. This reduced the size of the outer shell of the particle leading to a net 
decrease in particle size. Comparison of batch variation shows that the synthesis 
produced particles that showed no significant difference (T-Test) when the dynamic 
light scattering and zeta potential measurements where compared. 
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Formulation Particle Size (nm) Zeta Potential (mV) 
 
Solid Content 
(%) 
 
Core 
 
 
40.4±1.0 
 
-40.2±1.8 
 
10.3±0.6 
 
1:3 OPHP:EGDMA 
 
 
72.5±1.8 
 
-49.8±1.5 
 
14.2±0.3 
 
1:1 OPHP:EGDMA 
 
 
100.0±6.7 
 
-47.7±1.8 
 
10.0±0.7 
 
3:1 OPHP:EGDMA 
 
 
161.1±1.6 
 
-49.3±0.5 
 
13.2±0.1 
Figure 4.1 (A) Particle size analysis of OPHP:EGDMA latex. Batch variation analysed via Mann-Whitney T-Test. 
(B) Zeta potential analysis of OPHP:EGDMA latex. Batch variation analysed via Mann-Whitney T-Test. (C) 
Particle size, zeta potential and solid content measurements. 
The solid content analysis of OPHP:GMAC:EGDMA particles (Table 4-1) was less 
than those for OPHP:EGDMA particles but still within the normal range for this types 
of emulsion polymerisation. After deprotection of the GMAC shell, the deprotected 
and protected particle size were compared, as shown in Figure 4.2. The deprotection 
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step increases the swelling of the GMAC shell. The size range of the latex particles 
showed a wide variation depending upon the quantity of GMAC in the sample.   As 
the quantity of GMAC was increased, the particle size also increased. There was only 
a small increase in particle size between 2:1:1 OPHP:GMAC:EGDMA and 4:3:1 
OPHP:GMAC:EGDMA before deprotection. However, after deprotection this size 
difference increased. It is thought that before deprotection, GMAC was only a small 
crosslinking unit so additional protected GMAC in the particle shell does not have a 
vast effect upon particle size. After deprotection of the GMAC, the shell expanded in 
size and produced a porous layer. This effect was large enough to produce a 
noticeable effect on the net particle size.  
Comparison of batch variation shows that the synthesis produces particles in which 
the batch variation changes with a change in composition. There was a significant 
difference between the batch variation for particle size measurements for protected 
variants of 2:1:1 OPHP:GMAC:EGDMA particles (P=0.03) and 4:1:3 
OPHP:GMAC:EGDMA particles (P=0.04). Protected 4:3:1 OPHP:GMAC:EGDMA 
particles showed no significant difference in batch variation for zeta potential or 
particle size analysis. Protected 4:1:3 OPHP:GMAC:EGDMA particles also showed a 
significant batch variation for zeta potential measurements (P=0.009). Deprotected 
OPHP:GMAC:EGDMA showed no significant difference in batch variation when 
particle size or zeta potential where analysed.  
Formulation Solid Content (%) 
  
4:1:3 OPHP: GMAC:EGDMA 
 
 
7.5±0.04 
 
2:1:1 OPHP: GMAC:EGDMA 
 
 
7.9±0.05 
 
4:3:1 OPHP: GMAC:EGDMA 
 
 
 
7.6±0.6 
Table 4-1 Solid content analysis of 4:1:3 OPHP:GMAC:EGDMA, 2:1:1 OPHP:GMAC:EGDMA and 4:3:1 
OPHP:GMAC:EGDMA shell particles. 
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Formulation Zeta Potential 
Before De-
protection (mV) 
Zeta Potential 
After De-
protection (mV) 
 
Particle Size 
Before De-
protection 
(nm) 
Particle Size 
After De-
protection (nm) 
 
4:1:3 OPHP: 
GMAC:EGDMA 
-39.13±2.29 -16.28±1.76 78.37±4.83 
 
172.09±1.17  
2:1:1 OPHP: 
GMAC:EGDMA 
-35.36±2.18 -17.23±1.78 72.18±5.59 486.59±6.74 
4:3:1 OPHP: 
GMAC:EGDMA 
 
-41.45±2.46 -12.53±2.12 101.03±7.5 
 
861.22±14.09 
Figure 4.2 (A) Particle size measurements from protected GMAC containing latexes. (B) Zeta potential 
measurements from protected GMAC containing latexes. (C) Particle size measurements from deprotected 
GMAC containing latexes. (D) Zeta potential measurements from deprotected GMAC containing latexes. (E) 
Particle size, zeta potential and solid content analysis of GMAC containing latexes. Bach variation analysed via 
Mann-Whitney T-Test. 
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TEM imaging was undertaken on 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA 
particles. These were chosen as they showed the best performance in initial protein 
release studies (discussed in section 4.3). TEM imaging was used to confirm 
dynamic light scattering measurements and to examine particle morphology. 
Unfortunately TEM could only be performed upon protected OPHP:GMAC:EGDMA 
particles as the deprotected OPHP:GMAC:EGDMA particles showed significant 
aggregation and instability when imaged. This can be seen in Figure 4.3. 
 
Figure 4.3 (A) TEM image of 50:50 OPHP:EGDMA. (B) TEM image of protected 50:50 OPHP:GMAC:EGDMA 
particle. The core shell structure can be seen on both images. Particles stained with uranyl formate. (C) TEM 
image of PS-co-DVB particle core. Particles stained with uranyl formate. (D) TEM image of deprotected 50:50 
OPHP:GMAC:EGDMA particles. Aggregation and instability during the imaging process is seen. 
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 Analysis of PAMPS functionalised core-shell particles 
 
Particles containing L-PAMPS and B-PAMPS should bind heparin binding growth 
factors through the sulfonic acid groups present within the particle shell. It was 
hypothesised that a variation in shell architecture would affect the protein release. 
The L-PAMPS forms a grafted comb around the PBMA core. This makes the particle 
shell flexible and non-porous. Alternatively, the B-PAMPS forms a network around 
the PBMA [221].  
Before protein studies could be carried out, the branched and L-PAMPS were 
washed with PBS. The particle size measurements before washing showed that 
there are two distinct particle sizes present in the latex sample [221]. Figure 4.4 
shows the change in particle size distribution after washing. Each sample had 
narrow size distributions and only one particle size region is seen. This is due to the 
smaller particles being removed during the washing process. When the samples 
were centrifuged the smaller particles did not fully settle into a pellet. After several 
series of washings this resulted in the smaller particles being removed from the 
sample.  
Comparison of batch variation shows that the synthesis produced materials that 
exhibited some batch variation when analysing the particle size and zeta potential 
of the latexes. There was no batch variation in L-PAMPS when measuring particle 
size but did show batch variation when analysed for zeta potential (P=0.001). B-
PAMPS exhibited batch variation when analysed for particle size (P=0.01) but not 
when the zeta potential was measured.  
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 Particle size (nm) Zeta potential (mV) 
 
Linear PAMPS 
 
 
188.2±1.2 
 
-17.9±1.6 
 
Branched PAMPS 
 
 
113.1±0.4 
 
-65.5±1.3 
Figure 4.4 (A) Particle size distribution of repeated particle size measurements of L-PAMPS and B-PAMPS. (B) 
Zeta potential distribution of repeated measurments of L-PAMPS and B-PAMPS. (C) Average particle size and 
zeta potential measurements of L-PAMPS and B-PAMPS. Batch variation analysed by one-way ANOVA.  
 
 Protein release from OPHP functionalised core-shell particles 
 
The various ratios of phosphate to crosslinker were initially investigated for the 
release of VEGF. The aim was to produce a system that did not exhibit the normal 
burst release that is seen with similar protein delivery polymers [116].  
4.3.1 Release of VEGF165 
4.3.1.1 Preliminary studies 
Figure 4.5 shows the release of VEGF from 1:1 OPHP:EGDMA, 1:4 OPHP:EGDMA and 
3:1 OPHP: EGDMA shells over 72 hours. All particles show the same behaviour up to 
48 hours. At 72 hours the 1:3 OPHP: EGDMA and 3:1 OPHP:EGDMA release 
considerably more VEGF than the 1:1 particle. The 1:1 OPHP:EGDMA particles 
showed a more stable release profile. These particles were used for extended 
studies and also for comparison studies using different proteins.  
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The release of VEGF from particles containing the various ratios of 
OPHP:GMAC:EGDMA was also investigated for 72 hours (Figure 4.6). From 0-12 
hours the release of VEGF from each particle is very similar. After 12 hours the 
varying ratios of GMAC have an effect on the release profile of VEGF. The release 
from 4:3:1 OPHP:GMAC:EGDMA plateaued after 12 hours. Finally, the release from 
the 2:1:1 OPHP:GMAC:EGDMA particles is sustained over the 72 hours of the 
investigation. It is hypothesised that the VEGF is able to bind within the shell and is 
stabilised sufficiently to give a sustained release. The 2:1:1 OPHP:GMAC:EGDMA 
particles were chosen for further study and comparison studies with different 
growth factors. However, all particles show a burst release profile in the initial time 
points. 
 
Figure 4.5 Release of VEGF from various OPHP:EGDMA shell particles . 200ng protein initially loaded onto 
each sample. Analysis was performed with ELISA and all samples were ran in triplicate. (A) Cumulative 
release of VEGF over 72 hours. (B) Instantaneous release of VEGF at each time point over 72 hours. 
Figure 4.6 Release of VEGF from various OPHP:GMAC:EGDMA shell particles . 200ng protein initially loaded 
onto each sample. Analysis was performed with ELISA and all samples were ran in triplicate. (A) Cumulative 
release of VEGF over 72 hours. (B) Instantaneous release of VEGF at each time point over 72 hours. 
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4.3.1.2 31 day release studies 
For the full release profile of VEGF from phosphate functionalised core-shell 
particles to be determined, the study was extended to 31 days. Table 4-2 shows high 
initial VEGF uptake for both OPHP:EGDMA and OPHP:GMAC:EGDMA particles. This 
would be expected as both particles contain the same quantity of functional 
phosphate units. However, the initial VEGF loading data must not be viewed alone. 
The final quantity of VEGF retrieved from the particles must also be taken into 
consideration when determining which particles have better stabilisation 
properties.  Figure 4.7 shows the release of VEGF for 31 days. After 31 days 
approximately 69% of VEGF had been retrieved from OPHP:EGDMA particles 
whereas 100% VEGF had been retrieved from OPHP:GMAC:EGDMA particles. This 
indicates that the GMAC containing particles were better at stabilising VEGF 
compared to OPHP:EGDMA particles.  
Particle shell 1:1 OPHP:EGDMA 2:1:1 OPHP:GMAC:EGDMA 
Initial VEGF loading (%) 97.9±0.62 97.8±0.65 
Table 4-2 Initial VEGF uptake from 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA. VEGF loading was 
determined by analysis (ELISA) of the supernatant after loading protein onto the particles. 
After 24 hours the release profile of OPHP:EGDMA and OPHP:GMAC:EGDMA 
particles began to vary significantly (RM two-way ANOVA with Tukey post hoc 
analysis, P=0.0018). Figure 4.7 shows that OPHP:EGDMA released VEGF in a slower 
sustained manner whereas VEGF release from OPHP:GMAC:EGDMA particles 
plateaued after 24 days.  Since both particles contained the same quantity of 
phosphates (the unit that can bind to VEGF) the variety in release profile must be 
due to the shell architecture. However, when all the data are taken into 
consideration, OPHP:GMAC:EGDMA particles are better at stabilising VEGF than 
OPHP:EGDMA. 
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Figure 4.7 Release of VEGF over 31 days from OPHP:EGDMA and OPHP:GMAC:EGDMA particles. Particles 
were initially loaded with 100ng/ml VEGF solution. All samples were ran in triplicate and analysis was 
performed via ELISA. Data analysis was performed using RM-two-way ANOVA with Tukey post hoc analysis. 
4.3.2 Release of PDGF-BB 
The release profile of PDGF from 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA 
was determined. Table 4-3 shows the initial loading onto the particles. Both 
OPHP:EGDMA and OPHP:GMAC:EGDMA particles show good uptake. However, as 
previously discussed, these data must be considered alongside the data shown in 
Figure 4.8. When this is taken into consideration it shows that neither particles 
exhibited exceptional stabilisation of PDGF.  OPHP:GMAC:EGDMA particles (53.1% 
recovery) were significantly better at stabilising PDGF compared to OPHP:EGDMA 
particles (29.7% recovery). 
Particle Shell 1:1 OPHP:EGDMA 2:1:1 OPHP:GMAC:EGDMA 
Initial PDGF loading (%) 96.5±0.2 96.2±0.08 
Table 4-3 Initial PDGF uptake of 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles. Uptake was 
determined by analysis (ELISA) of the supernatant after PDGF loading. 
The release of PDGF from OPHP:EGDMA and OPHP:GMAC:EGDMA particles 
produced similar release profiles, but significantly different quantities of protein 
were detected after release. Both particle compositions gave an initial burst release 
then began to plateau after 7 days. OPHP:GMAC:EGDMA particles stopped releasing 
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any significant amount of PDGF after 10 days whereas small quantities of  PDGF 
were detected from OPHP:EGDMA particles for the full 31 days. 
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Figure 4.8 Release of PDGF over 31 days from OPHP:EGDMA and OPHP:GMAC:EGDMA particles. Particles 
were initially loaded with 100ng/ml PDGF solution. All samples were ran in triplicate and analysis was 
performed via ELISA. Data analysis was performed using RM-two-way ANOVA followed by Tukey post hoc 
analysis. 
PDGF is smaller than VEGF (PDGF 24.4KDa compared to VEGF 38.2KDa) and this 
results in PDGF being released faster from OPHP:GMAC:EGDMA than OPHP:EGDMA 
particles. The pores of the OPHP:GMAC:EGDMA shell would not necessarily slow the 
release of PDGF as it would be too small for a size exclusion effect to be exerted by 
the GMAC shell. The pores in the OPHP:EGDMA shell are smaller than those in the 
OPHP:GMAC:EGDMA shell. The PDGF was able to bind deep within the 
OPHP:EGDMA shell, slowing the release profile. 
4.3.3 Release of EGF 
The release of EGF from 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles 
was investigated. EGF is a small protein that does not specifically bind to heparin. It 
was chosen as a candidate for investigation due to its size and presence of arginine 
and lysine units. Table 4-4 showed good protein uptake from each of the particles. 
However, the data shown in Table 4-4 is not necessarily correct. The particles did 
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not bind a high proportion of the protein. Instead, the protein was not stabilised and 
was unable to be detected by ELISA, as shown in Figure 4.9. This gives the initial 
impression that there is no EGF left in the supernatant after protein binding.  
Particle Shell 1:1 OPHP:EGDMA 2:1:1 OPHP:GMAC:EGDMA 
Initial EGF loading (%) 99.6±1.92 99.6±0.97 
Table 4-4 Initial EGF uptake of 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles. Uptake was 
determined by analysis of the supernatant after EGF loading. 
The release profile of EGF from 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA is 
almost identical. The release profile is steady over 24 hours but very small 
quantities of protein are released. This could be because the protein was not 
stabilised sufficiently by the particles. Once the protein was degraded it could no 
longer be detected by ELISA. This would explain why there was such small protein 
recovery from OPHP and GMAC particles.  
 
 
Figure 4.9 shows that the particle shell architecture had no effect on the release of 
EGF. This was because EGF is extremely small compared to the other proteins (EGF 
6.3kDa, PDGF 24.3kDa and VEGF 38.2kDa). The large pores in OPHP:GMAC:EGDMA 
shell and small pores in OPHP:EGDMA shell had no effect on the release of EGF as it 
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Figure 4.9 Release of EGF over 24 hours from OPHP:EGDMA and OPHP:GMAC:EGDMA particles. Particles 
were initially loaded with 100ng/ml EGF solution. All samples were ran in triplicate and analysis was 
performed via ELISA. Data analysis was performed using RM-two-way ANOVA followed by Tukey post hoc 
analysis. 
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was too small to have significant size exclusion effect on release.  This resulted in a 
fast release with little to no stabilisation.  
 
 Protein release from PAMPS functionalised core-shell particles 
 
4.4.1 Release of VEGF165 
The binding and subsequent release of VEGF was studied over 31 days. The quantity 
of PAMPS and the architecture of the particle shell were varied. The release profile 
indicates that the quantity of PAMPS plays a less significant role in the release of 
VEGF than the shell architecture (see Figure 4.10). This is due to the large excess of 
potential binding points on the particles. This means that even the lower quantity of 
PAMPS included in the particles still has many free sulfonic acid groups that VEGF 
could bind to. Increasing the available sulfonic acid groups, therefore, does not affect 
the ability to bind VEGF and the subsequent release profile.  
The initial protein uptake was high for L-PAMPS and B-PAMPS (Table 4-5).  
Branched particle data initially indicated that they were able to bind slightly higher 
amounts of VEGF than linear particles. However, when viewed in combination with 
the final detectable protein shown in Figure 4.10 this may not be the case. Any 
denatured protein cannot be detected by the ELISA protocol so if the branched 
particles could not stabilise the VEGF sufficiently, this may give a misleading result 
for initial protein uptake.  
Particle shell 1g Linear 
PAMPS 
4g Linear 
PAMPS 
1g Branched 
PAMPS 
4g Branched 
PAMPS 
Initial VEGF loading (%) 97.7±0.27 98.7±0.3 99.7±0.3 99.7±0.24 
Table 4-5 Initial uptake of VEGF from a solution containing VEGF in PBS with 0.1 % BSA bound to PAMPS 
coated latex particles. Protein analysis carried out via ELISA. 
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The general release profiles are similar for both quantities of PAMPS. The L-PAMPS 
shows a release profile with sustained release up to 31 days and no burst release 
phase was seen in the initial time points. The B-PAMPS shows initial release that 
begins to slow or plateau after 9-10 days. This could be due to the protein size, 
PAMPS shell architecture and shell flexibility. The recombinant VEGF used has a 
molecular weight of 38.2 KDa. It can be reasoned that the L-PAMPS shell is flexible 
and can accommodate a protein of this size. This could stabilises the protein (in a 
similar manner as HS) whilst it is bound to the PAMPS and slows the release by 
A 
B 
Figure 4.10 Release of 100ng/ml VEGF from particles containing either L- or B-PAMPS. (A) 1g PAMPS 
surrounding a PBMA core. (B) 4g PAMPS surrounding a PBMA core. All samples were studied in triplicate and 
analysed by ELISA. RM-two-way ANOVA with Tukey post hoc analysis was used. 
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binding to many sulfonic acid groups as it moved through the particle shell. This 
leads to a high binding and stabilisation, followed by a slow sustained release that 
yields approximately 95% for 1g L-PAMPS particles and 94% for 4g L-PAMPS after 
31 days. In comparison, the branched particle shell can be thought of as a rigid 
porous structure. If the VEGF is not of the correct size to fit within these pores, the 
protein can only bind to the sulfonic acid groups available on the particle surface. 
This would reduce the stabilisation of protein, reducing the ability of detection once 
released and would produce a particle that exhibits a burst release profile. This is 
what can be seen with both 1g and 4g B-PAMPS. Due to reduced protein 
stabilisation, after 31 days only approximately 50% for 1g B-PAMPS and 58% for 4g 
B-PAMPS of the initial VEGF was detected.     
4.4.2 Release of PDGF-BB 
The release of PDGF was also studied over 31 days. As discussed in section 4.4.1, the 
particle architecture played a greater role in tailoring the release profile than the 
quantity of PAMPS included in the particle shell. The initial uptake (seen in Table 
4-6) indicates that L-PAMPS has a marginally better initial protein uptake when 
compared to B- PAMPS. However, when the final protein recovery data (Figure 4.11) 
are taken into consideration, the initial uptake data may not be an accurate 
representation of protein binding and stabilisation. 
  Particle shell 1g Linear 
PAMPS 
4g Linear 
PAMPS 
1g Branched 
PAMPS 
4g Branched 
PAMPS 
Initial PDGF loading (%) 99.5±0.24 99.0±0.25 98.7±0.47 96.9±0.28 
Table 4-6 Initial uptake of PDGF from a solution containing PDGF with 0.1 % BSA bound to PAMPS coated 
latex particles. Protein analysis carried out via ELISA. 
PDGF is a relatively small protein of 24.4 KDa. The size of PDGF compared to VEGF 
affects how the PAMPS shell can stabilise and release the protein. Both the 1g and 
4g PAMPS particles showed that B-PAMPS releases more detectable PDGF over 31 
days then L-PAMPS.  
Two effects could be occurring with the PDGF release data. The first is that the 
branched porous shell allows the PDGF to bind within the particle. This would 
produce better stabilisation of the PDGF over the study time, allowing for more 
PDGF to be detected at each time point. The linear shell cannot stabilise the protein 
over long periods of time, so less protein is detected at each time point. 
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Alternatively, PDGF is well stabilised and was released extremely slowly by both the 
L-PAMPS and B-PAMPS shells. However, the data indicated that the first case is the 
most likely in this example. This is because as the quantity of B-PAMPS in the shell 
was increased from 1g to 4g, slightly more protein was detectable after 31 days 
(30.5ng to 36.3ng PDGF). This provides evidence that more available PAMPS 
increases the ability to stabilise more PDGF, hence more is detected at final time 
points. Overall, the protein retrieval is low after 31 days (between 10.8-14.3% for L-
PAMPS and 30.5-36.3% for B-PAMPS).  
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4.4.3 Release of EGF 
EGF was released from linear and branched PAMPS over 24 hours. The initial EGF 
loading shows high percentage of protein uptake. However, as previously discussed, 
this is not an accurate representation of what was occurring. When viewed with 
Figure 4.12 it shows that the EGF was not sufficiently stabilised by the 1g PAMPS 
particles, leading to little or no detection in the supernatant.  
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Figure 4.11 Release of 100ng/ml PDGF from particles containing either L- or B-PAMPS. (A)1g PAMPS 
surrounding a PBMA core. (B) 4g PAMPS surrounding a PBMA core. All samples were studied in triplicate and 
analysed by ELISA. RM-two-way ANOVA with Tukey post hoc analysis was performed. 
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Particle shell 
 
Linear PAMPS 
 
Branched PAMPS 
 
 
Initial EGF loading (%) 
 
 
81.9±2.98 
 
99.6±0.64 
Table 4-7 Initial uptake of EGF from a solution containing EGF with 0.1 % BSA bound to PAMPS coated latex 
particles. Protein analysis carried out via ELISA. 
The release profile of EGF from L-PAMPS and B-PAMPS is shown in Figure 4.12. 
There is no significant difference between the release from L-PAMPS or B-PAMPS. 
Both B-PAMPS and L-PAMPS showed a plateau region beginning to form after 12 
hours. The linear particles showed a slight increase in the quantity of released EGF 
compared to branched particles. However, the quantity of protein released from 
each was extremely small and would not be practically useful.  
As previously discussed, EGF is not a heparin binding growth factor but does have 
characteristics similar to VEGF and PDGF. When compared to VEGF and PDGF, EGF 
is a significantly smaller protein. The pores produced in the B-PAMPS shell have no 
influence on the release of EGF, as the protein is too small to have any significant 
electrostatic interactions as it is released. This resulted in poor initial binding, 
reduced stabilisation of the protein and finally very little intact protein release from 
the particles. 
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Figure 4.12 Release of EGF from 1g L- and B-PAMPS over 24 hours. Samples were loaded with 100ng/ml EGF 
and analysed in triplicate via ELISA. Statistical analysis was doen using RM-two-way ANOVA with Tukey post 
hoc analysis. 
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 Analysis of NVP-co-DEGBAC hydrogels 
 
PVP-co-DEGBAC hydrogels with embedded core-shell polymer particles can be 
synthesised by thermal and UV curing. The four types of core-shell particles 
embedded in the gel shows some variation in the water content analysis. 
Initial formulation experiments were completed with thermally cured hydrogels. 
The percentage of latex embedded was varied from 5% to 40% latex. The smaller 
weight % of particles had no detrimental effect on the composition of the latex and 
the larger weight % prevented the hydrogel from successfully curing. The quantities 
stated in Table 3-4 produced the easiest to handle hydrogels.  Thermally curing the 
hydrogels highlighted two problems. The first was the slow production rate due to 
the need for an overnight cure. The second was small nitrogen bubbles forming in 
the gel upon curing. This was due to the nitrogen release from the azo-initiator. Even 
with thorough degassing this problem was maintained. UV curing was chosen to be 
the main method of curing the hydrogels. All protein experiments were completed 
using UV cured hydrogels. This is because there is a faster synthesis rate with UV 
cured hydrogels and they produced a more consistent gel (no bubbles formed). With 
a medium to low percentage of latex included in the hydrogel, the polymer could still 
cure using UV, indicating that the solid particles were not significantly negatively 
affecting radical production and curing efficiency. All hydrogels were extremely 
brittle without the inclusion of propan-2-ol as a solvent. Upon adding solvent the 
hydrogels were softer and could be cut using a cork borer.  
Table 4-8 shows the water content of each hydrogel. They are all within the region 
of 81-88% water content. These hydrogels are designed as wound dressing and a 
high water content is a desirable feature [241]. The PVP-co-DEGBAC control 
hydrogel and those containing L-PAMPS, OPHP and GMAC all have very similar 
water contents. This would be expected as the percentage of components in each gel 
is very similar. The PVP-co-DEGBAC hydrogel containing B-PAMPS has a higher 
water content. This hydrogel has the same ratios of monomers as the PVP-co-
DEGBAC L PAMPS gel. This indicated that the increase in water content is due to the 
B-PAMPS present on the surface of the core shell particles embedded within the 
hydrogel. Previous studies have shown that as the molar ratio of PAMPS is increased 
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this can increase the polymer swelling in water [261]. The shell on the B-PAMPS 
particles is more porous and has the ability to hold slightly more water than the L-
PAMPS shell.  
Material Water content (%) 
PVP-co-DEGBAC control 85.37 ± 1.2 
PVP-co-DEGBAC B PAMPS 88.68 ± 0.9 
PVP-co-DEGBAC L PAMPS 86.35 ± 0.66 
PVP-co-DEGBAC OPHP 86.56 ± 0.87 
PVP-co-DEGBAC GMAC 86.21 ±2.26 
Table 4-8 Water content (%) of UV cured hydrogel controls and hydrogels containing core shell polymer 
particles. 
Figure 4.13 shows the SEM images taken of the surface of the gel and the edge of the 
gel. The control material and those containing particles both had a ridged surface; 
this is from the drying process. When water was lost from the hydrogel the polymer 
collapsed in on itself forming a material with a ridged appearance. The edges of the 
hydrogels show a fractured polymer. This is because the material becomes brittle 
when dried. Debris is also present around the edges of the hydrogels. The details of 
the internal structure may be lost when the gel is dried.  
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Figure 4.13 SEM images of PVP-co-DEGBAC hydrogels containing the core shell particles. (A) surface of control (B) 
edge of control (C) surface of OPHP:EGDMA particle containing polymer (D) edge of OPHP:EGDMA particle containing 
polymer (E) surface of OPHP:GMAC:EGDMA particle containing polymer (F) edge of OPHP:GMAC:EGDMA particle 
containing polymer (G) surface of L-PAMPS particle containing polymer (H) edge of L-PAMPS particle containing 
polymer (I) surface of B-PAMPS particle containing polymer (J) edge of B-PAMPS containing polymer. 
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   Protein release from particles embedded in NVP-co-DEGBAC hydrogels 
 
The release of VEGF, PDGF and EGF over 3 days was investigated. The release profile 
would be expected to be similar to that determined in chapters 3 and 4. The PVP-co-
DEGBAC control gel should not bind any significant quantities of protein because 
there is not a binding target on the surface of the hydrogel. 
4.6.1 Release of VEGF 
Figure 4.14 shows VEGF release from PVP-co-DEGBAC control gels and hydrogels 
with either 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, L-PAMPS or B-PAMPS. 
The release from the control, 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA 
showed no significant difference in release. VEGF was initially released in a burst 
between 0 and 1 hour. After this point the release plateaus and no more VEGF is 
released.  
The release profile from L-PAMPS embedded in PVP-co-DEGBAC gels closely 
matched those of the particle alone. The release profile is linear and significantly 
differs from the control after 1 hour. The release profiles of B-PAMPS particles are 
similar to that of the L-PAMPS particles. The release profile from B-PAMPS 
embedded in PVP-co-DEGBAC gels closely matched those of the particle alone up to 
the same time point.  
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Figure 4.14 Release of VEGF from 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, B-PAMPS and L-PAMPS 
particles embedded in PVP-co-DEGBAC hydrogel. The control is PVP-co-DEGBAC hydrogel with no embedded 
particles. Two-way ANOVA with TUKEY post-hoc analysis was performed 
4.6.2 Release of PDGF 
Figure 4.15 shows the release of PDGF from PVP-co-DEGBAC control hydrogels and 
hydrogels with 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, L-PAMPS and B-
PAMPS particles embedded in the gel. The control hydrogel, 1:1 OPHP:EGDMA and 
2:1:1 OPHP:GMAC:EGDMA show no significant difference in the release profile of 
PDGF. There was a large percentage of the PDGF washed off the hydrogels at time 
point 0 (between 40-60% of the protein loaded). After this there was a small burst 
release between time point 0 and 1 hour. The release profile of PDGF from 1:1 
OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles without the hydrogel 
showed protein released at each time point up to 72 hours.  
L-PAMPS and B-PAMPS show some difference in release profile compared to the 
control. They are both lower than the control and show little to no release over the 
72 hours. L-PAMPS hydrogels show only very small amounts of protein detected at 
each time point. There is approximated 30% of the loaded protein detected at time 
point 0 from the B-PAMPS hydrogel and this does not vary over the course of 72 
hours.  This suggest that neither the L-PAMPS or B-PAMPS are stabilising the PDGF 
enough for degradation to be prevented and the protein to be detectable. The 
release profiles differ considerably to the data from the particles with no hydrogel. 
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Over the same time period studied by the hydrogel experiment, both L-PAMPS and 
B-PAMPS showed cumulative release of PDGF. L-PAMPS only released small 
portions of PDGF, however, more PDGF was released with the particles alone than 
those embedded in hydrogels. B-PAMPS released larger portions of PDGF in a 
relatively linear fashion.  
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Figure 4.15 Release of PDGF from 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, B-PAMPS and L-PAMPS 
particles embedded in PVP-co-DEGBAC hydrogel. The control is PVP-co-DEGBAC hydrogel with no embedded 
particles. Two-way ANOVA with TUKEY post-hoc analysis was performed 
4.6.3 Release of EGF 
Figure 4.16 shows the release profile of EGF from PVP-co-DEGBAC control hydrogels 
and hydrogels with 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, L-PAMPS and B-
PAMPS particles embedded in the gel. There is no significant difference between the 
control and any gels containing particles. The protein recovery is low and the release 
profile is similar to that of the particles with no hydrogel. Due to the release profile 
of the particle containing hydrogels being so similar to that of the control, this 
suggests that the EGF is not sufficiently electrostatically bound to the negative 
charges present on the particles to stabilise the protein. This results in small 
quantities being detected (between 2.1-3.9% proteins recovered after 72 hours) and 
there being no difference between charged particles and a neutral hydrogel.  
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The overall efficiency of binding and release of all proteins from each material is 
reduced or equal to that of the particles alone. This is due to the hydrogel reducing 
the functionality of the particles and the availability of phosphate and sulphonic acid 
groups leading to a reduction in protein binding, stability and release.  The 
behaviour of the particles within the gel is not yet fully understood.  
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Figure 4.16 Release of EGF from 1:1 OPHP:EGDMA, 2:1:1 OPHP:GMAC:EGDMA, B-PAMPS and L-PAMPS 
particles embedded in PVP-co-DEGBAC hydrogel. The control is PVP-co-DEGBAC hydrogel with no embedded 
particles. Two-way ANOVA with TUKEY post-hoc analysis was performed 
 
 Synthesis and analysis of acryloxyethyl thiocarbamoyl rhodamine B labelled 
particles 
 
The aim was to produce fluorescent particles that could be used to track particle 
movement in vivo. Acryloxyethyl thiocarbamoyl rhodamine B was successfully 
incorporated into four different formulations. However, the long term stability was 
poor resulting in aggregation and coagulation. This reduced the practicality of the 
material. 
4.7.1 Synthesis of acryloxyethyl thiocarbamoyl rhodamine B labelled particles  
The synthesis of acryloxyethyl thiocarbamoyl rhodamine B labelled particles was 
attempted using a variety of methods. To begin with the fluorescent dye was added 
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to the shell of PS-co-DVB core poly (OPHP-co-EGDMA) shell latexes. This lead to 
significant coagulation after 16-18 hours at 4oC. This was deemed to be because the 
positive charge on the acryloxyethyl thiocarbamoyl rhodamine B was destabilising 
the latex, acting as a salt. Hence for the syntheses described the acryloxyethyl 
thiocarbamoyl rhodamine B was added to the PS-co-DVB core and poly (OPHP-co-
EGDMA) shell and PS-co-DVB core poly(OPHP-co-EGDMA-co-GMAC) shell added 
after incorporation of  acryloxyethyl thiocarbamoyl rhodamine B. The second 
reaction was completed in a continuous process and the remaining acryloxyethyl 
thiocarbamoyl rhodamine B core was not isolated from the reaction mixture. 
Therefore, it was assumed that although the majority of the label was in the particle 
core, there was a possibility that the label was also present in the particle shell.  
The synthesis of both L PAMPS and B PAMPS stabilised PBMA particles was 
attempted using the equivalent of 1g PAMPS. Initially these latexes appeared stable, 
however, after 3 days the latexes coagulated. The quantity of PAMPS was too low to 
act as a sufficient surfactant for the BMA core when acryloxyethyl thiocarbamoyl 
rhodamine B was added to the system. A larger quantity (equivalent to 4g) of both 
L-PAMPS and B-PAMPS was used for the synthesis. This remained visually stable for 
several weeks at 4oC. Due to the one-step method used to synthesise PAMPS shell 
particles, the exact location of acryloxyethyl thiocarbamoyl rhodamine B cannot be 
determined. It will be incorporated in both the shell and core of the particle.  
All particles were unstable if left in the original reaction mixture without dialysis. 
Dialysis was carried out at 4oC straight after completion of the reaction. As the latex 
was dialysed some of the acryloxyethyl thiocarbamoyl rhodamine B label was being 
washed out of the solution. This occurred until 3-4 cycles of dialysis had been 
completed. After this the label could no longer be seen in the wash solutions. The 
instability of the particles when un-dialysed and the obvious washing out of some 
label indicated that even at 0.1% label, not all was incorporated into the polymer. If 
free label was present in the reaction mixture it would destabilise the particles 
because rhodamine B contains a positive charge and the particles contain a negative 
change. 
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4.7.2 Analysis by dynamic light scattering, zeta potential measurements and solid 
content analysis 
Dynamic light scattering showed that the particles containing the label have a 
relatively uniform size and similar size distribution to those with no label [221]. The 
PS-co-DVB core was considerably larger than the core with no acryloxyethyl 
thiocarbamoyl rhodamine B (see Figure 4.1). The size of 1:1 OPHP:EGDMA core-
shell system was also increased compared to those that did not contain a label in the 
core (Figure 4.1). This size increase indicates that the label has been polymerised 
into the particle [262]. Zeta potential measurements (Table 4-9) show all particles 
to be stable and contain a negative charge. The solid content is also in the expected 
region. 
Formulation Particle Size (nm) Zeta Potential (mV) 
 
Solid Content 
(%) 
PS-co-DVB core 
 
121.9 ± 1.0 -37.4 ± 1.5 12.9 ± 0.2 
1:1 OPHP:EGDMA 
 
265.3 ± 3.2 -44.9 ± 1.3 10.2 ± 0.7 
2:1:1 
OPHP:GMAC:EGDMA 
 
See Table 4-10 See Table 4-10 See Table 4-10 
Linear PAMPS 
 
149.0 ± 1.0 -45.3 ± 1.6 16.6 ± 0.1 
Branched PAMPS 
 
112.2 ± 1.8 -47.3 ± 2.1 14.8 ± 0.4 
Table 4-9 Particle size, zeta potential and solid content analysis of core shell particles synthesised with 
acryloxyethyl thiocarbamoyl rhodamine B. All samples ran in triplicate. Data shows mean ± SE. 
2:1:1 OPHP:GMAC:EGDMA particles behaved differently to the others when 
acryloxyethyl thiocarbamoyl rhodamine B label was incorporated in the 
polymerisation. Table 4-10 shows the values for particle size, zeta potential and 
solid contents of protected and de-protected particles. The particle size of 2:1:1 
OPHP:GMAC:EGDMA particles containing a label is smaller than that of the particles 
with no label even though the core is larger with a label (see Figure 4.2) for 
comparison with no label). One reason for this may be that the presence of 
acryloxyethyl thiocarbamoyl rhodamine B is retarding the polymerisation in both 
the core and the shell. It is well documented that fluorescent labels can retard 
polymerisation [234]. If the polymerisation of the core is not complete before the 
shell monomers are added the overall particle size will be smaller than anticipated. 
This is potentially what is occurring with the rhodamine B labelled GMAC polymers. 
 
 
82 
 
The particle size increases as expected upon de-protection therefore the shell is 
present on the particle. The lower than anticipated solid content also indicates that 
complete monomer conversion is not occurring. The OPHP:GMAC:EGDMA shell is 
less stable than OPHP:EGDMA shell (as indicated by zeta potential measurements). 
The incomplete particle core will have less of an obvious effect on the particle size 
since the more stable OPHP:EGDMA shell is able to accommodate the incorporation 
of a small quantity of acryloxyethyl thiocarbamoyl rhodamine B. This will destabilise 
the shell to some degree and this can be seen by comparing zeta potential 
measurements shown in Figure 4.1 (no label) and Table 4-9 (containing 
acryloxyethyl thiocarbamoyl rhodamine B). The OPHP:GMAC:EGDMA shell is less 
stable and cannot incorporate acryloxyethyl thiocarbamoyl rhodamine B without 
significant colloid disruption, hence a smaller particle is formed with a lower solid 
content.  
 Protected De-protected 
 
Formulation 
 
Particle 
Size (nm) 
 
 
Zeta 
Potential 
(mV) 
 
Solid 
Content 
(%) 
 
Particle 
Size 
(nm) 
 
Zeta 
Potential 
(mV) 
 
Solid 
Content 
(%) 
2:1:1 
OPHP:GMAC:EGDMA 
 
56.3 ± 0.9 -41.5 ± 2.1 8.1 ± 0.1 
 
314.8 ± 
6.9 
-35.2 ± 1.7 
 
3.6 ± 1.3 
Table 4-10 Particle size, zeta potential and solid content analysis of GMAC containing core shell particles 
synthesised with acryloxyethyl thiocarbamoyl rhodamine B before and after the deprotection of GMAC. All 
samples ran in triplicate. Data shows mean ± SE. 
 
4.7.3 Cell culture and endocytosis of particles 
Labelling of particles would enable them to be tracked when used in bio-assays in 
vitro and in vivo. First, it must be determined if cells envelop the labelled particles. 
Initial experiments resulted in problems when washing the cells and removing 
residual particles. This resulted in mechanical removal of cells in the centre of each 
well plate. Gentle washing was not always sufficient to remove any particles that 
had settled on the surface of the well plate and some settled particles could be seen. 
Figure 4.17 shows the result of too much or too little washing. By removing any 
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particles that are within the media the only particles visible should be those taken 
up by cells. 
Figure 4.17 also shows the effect of salt on the particles. For the cells to be able to 
survive the particles must be re-suspended in PBS followed by DMEM. This was 
shown to significantly de-stabilise OPHP:EGDMA and OPHP:GMAC:EGDMA 
particles. This resulted in the particles aggregating together, preventing cell uptake 
and limiting further use of the materials.  L-PAMPS and B-PAMPS particles 
containing a label showed a small amount of aggregation in DMEM. However, the 
aggregation was considerable enough to hind any further use of the fluorescent 
particles.  
 
 Protein degradation and analysis by alternative techniques 
 
Gel electrophoresis and mass spectrometry was used to determine if they are 
suitable analytical techniques for the release of proteins from negatively charged 
core-shell particles. The degradation of proteins was also investigated. Heparin was 
used as a comparison for the release of VEGF as VEGF binds to heparin when 
naturally released in the body.  
Gel electrophoresis with silver staining showed little difference between pure VEGF 
or PDGF and degraded VEGF or PDGF. The VEGF gel shows a marker for VEGF just 
higher that the marker for 37 KDa. This would be expected as the molecular weight 
of VEGF studies is 38.2 KDa. From visual inspection of the gel, the VEGF band is the 
Figure 4.17 40000 NHDF seeded onto 24 well plates with 250 µl OPHP:EGDMA shell fluorescent particles. 
(A) Imaged after heavy washing of surface to remove particles. Particle remnants and low cell count can be 
seen. (B) After removing particles by not washing surface. Scale bar 1000µm. 
A B 
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same in both the degraded and non-degraded proteins. There is also a band present 
around the 25 KDa mark. This is stronger stained and thicker in the degraded 
protein than the non-degraded protein. This band can be attributed to the VEGF 
dimer breaking in half. The fact that this is still present in the non-degraded gel 
indicates how sensitive to the aqueous environment and easily denatured VEGF can 
be. The strong peak present at approximately 60-70 KDa is the BSA that is present 
in both the lyophilised protein and when made into solution.  Mass spectrometry 
data confirmed the BSA peak at 66.4 KDa in both degraded and non-degraded 
samples. A peak present at 73.9 KDa was attributed to complexed VEGF and was 
present in both spectra. This peak may have ran into the BSA on the gel which would 
explain the thicker than expected band present. Small peaks were seen on both 
spectra between 45 KDa and 30 KDa. These peaks have been dwarfed by the larger 
BSA peak so the quantifying these peaks proved difficult.  
 
 
The PDGF gel shows a marker for PDGF around the marker for 25 KDa. This would 
be expected as the molecular weight of PDGF studied is 24.4 KDa. The PDGF band 
looks stronger in the degraded protein than the non-degraded protein. However, the 
bands are the same width, so the depth of staining may not be representative of the 
quantity of protein present. There are three bands present between the 25-20 KDa 
bands. These are thicker and more obvious in the degraded protein. This would 
indicate that these are products of protein degradation, although the exact products 
cannot be determined from this data alone. The BSA band at approximately 66.5 KDa 
Figure 4.18 Electrophoresis gels showing degraded protein and non-degraded protein. All samples, including 
standards, were run in triplicate. 
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can also be seen on the PDGF gel. Mass spectrometry data confirmed the BSA peak 
at 66.4 KDa in both degraded and non-degraded samples. A peak at 73.8 KDa in the 
degraded protein spectra and 73.9 KDa in the non-degraded spectra was attributed 
to a complex of three PDGF proteins. A further peak at 44.3 KDa was present in both 
spectra and was a complex of two proteins.  
VEGF was released from core-shell particles in the same manner as described in 
chapters 3 and 4. Both gels show a band for BSA and a band at ~38 KDa for VEGF. 
Both gels show light thin bands below 37 KDa that relate to degradation products. 
These would be expected as the protein has been released for 48 hours. The protein 
released in the early stages of the experiment would have begun to degrade in 
solution. In each gel well 7 shows darker bands at the same band position as the 
standard wells. This can be attributed to the standard wells running slightly. In all 
wells relating to the protein released from particles there is a dark band above 250 
KDa. This is any residual polymer that may have been in suspension after 
centrifuging the polymer/protein samples. The polymers are designed to be highly 
charged and because of this would not run down the gel. This is stronger in L-PAMPS 
and B-PAMPS compared to OPHP or GMAC wells. When centrifuging L-PAMPS and 
B-PAMPS particles it can take some time before a fine suspension is no longer 
present, therefore it is difficult to ensure no polymer contaminates supernatant 
samples. This behaviour has been explained by Platt et. al. as PAMPS particles were 
found to produce two defined particle sizes during colloid synthesis [221]. The mass 
spectrometry from released proteins was the same as those for VEGF as described 
above. 
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When released in the body VEGF is bound and stabilised by heparin that is present 
as part of the ECM. To investigate the effectiveness of core-shell particles for 
releasing VEGF, heparin was used as a comparison. The electrophoresis gel shows 
bands for BSA and a band at approximately 150 KDa that can be attributed to 
heparin. Because heparin is naturally derived, a definitive molecular weight is not 
given as the heparin may be a range of molecular weights. Wells 5-7 contain heparin 
with VEGF bound. The VEGF cannot be seen on the gel. This may be due to the 
heparin not running down the gel sufficiently. As discussed in chapter 1, heparin is 
a highly charged molecule. This can prevent movement down the electrophoresis 
gel when a voltage is applied. The lack of protein showing on the gel indicates that 
this is what has occurred. It also suggests that VEGF is bound tightly to heparin and 
is not continuously released as seen with core-shell particles. The highly charged 
nature of heparin also prevented any more information being gained from mass 
spectrometry.   
 
 
  
Figure 4.19 Electrophoresis gels showing VEGF that had been released from various core shell particles. All 
samples, including standards, were run in triplicate. 
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5 Discussion 
 Analysis of OPHP functionalised core-shell particles 
 
When producing a polymer for eventual large scale production, it is important to 
investigate the batch variation of particles synthesised by emulsion polymerisation. 
Figure 4.1 and Figure 4.2 show the batch variation in dynamic light scattering (DLS) 
and zeta potential analysis for OPHP:EGDMA and OPHP:GMAC:EGDMA latexes. Box 
and whisker plots not only show any batch variation, but also show the range of 
variation. The information gained from visual representation of the interquartile 
range is useful if the batch variation needed to be reduced.  
OPHP:EGDMA particles showed no significant difference between batch variation. 
OPHP:GMAC:EGDMA particles showed some significant difference when protected 
(2:1:1 OPHP:GMAC:EGDMA particle size, P=0.03; 4:1:3 OPHP:GMAC:EGDMA particle 
size, P=0.04, zeta potential, P=0.009) but no significant difference after deprotection 
of the GMAC unit. All materials containing GMAC exhibited an increase in size after 
deprotection. It is thought that this is due to the removal of acetone from GMAC 
units, producing glycerol mono-methacrylate polymerised into the particle shell. 
This unit is much more hydrophilic than GMAC, therefore, it can bind more water 
into the particle shell. This would cause the particle shell to swell, thereby, 
increasing the overall particle size that is measured via DLS. The data shown in 
Figure 4.2 validates the hypothesis that the particle size increase is due to 
deprotection of the GMAC unit. The material with the largest quantity of GMAC 
(4:3:1 OPHP:GMAC:EGDMA) has the largest particle size (861.22±14.09 nm) and the 
material with the smallest quantity of GMAC (4:1:3 OPHP:GMAC:EGDMA) has the 
smallest particle size (172.09±1.17 nm). 
Particle size was confirmed using TEM (Figure 4.3). However, deprotected 
OPHP:GMAC:EGDMA particles could not be successfully imaged using standard TEM 
techniques. When preparing samples for TEM imaging, the deprotected 
OPHP:GMAC:EGDMA particles became instable, aggregated into polymer clumps, 
and finally burnt or melted in the electron beam. This did not occur with protected 
OPHP:GMAC:EGDMA particles. This could be due to the reduction in the particle zeta 
potential upon deprotection. Figure 4.2 shows that for all GMAC containing 
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materials, the zeta potential is decreased upon deprotection. This would be 
expected. The negative charge on the polymer shell arises due to the negative 
phosphate groups present on the OPHP monomer. The quantity and availability of 
these groups does not change when the GMAC groups are deprotected, however, the 
size changes drastically. This results in the negative charge being spread over a 
larger surface area. If the particle charge is reduced upon deprotection, the particles 
would be less colloidally stable and more prone to aggregation. The future work 
section discusses alternative to standard TEM imaging for colloidally instable 
particles.  
Percentage solid content was determined for OPHP:EGDMA and 
OPHP:GMAC:EGDMA particles (shown in Figure 4.1 and Table 4-1). In emulsion 
polymerisations that produce insoluble cross-linked materials, solid content 
analysis can give insight into the degree of polymerisation. Comparison between the 
expected mass recovery (Table 3-5) and the actual mass recovery (Table 4-1 and 
Figure 4.1) shows that all syntheses were completed to a high degree of 
polymerisation. Any insignificant mass loss or gain when determining the 
percentage solid content could be due to material loss when weighing or residual 
water in the samples after drying. 
 
 Analysis of PAMPS functionalised core-shell particles 
 
Before use in protein release studies, L- and B-PAMPS particles had to be washed 
with distilled water. The particle size and zeta potential measurements were 
determined to ensure the washing steps did not affect the particles. Zeta potential 
and DLS analysis prior to washing can be found in the paper by Platt. et. Al. [221]. L-
PAMPS was shown to be larger (188.2±1.2 nm) and have a lower zeta potential (-
17.9±1.6 mv) than B-PAMPS. Both the L- and B-PAMPS containing the same quantity 
of PAMPS monomer (in this case 1g). The structure of each monomer (Figure 1.7) 
shows that B-PAMPS has more negative charges per repeating unit than L-PAMPS. 
B-PAMPS is also smaller (113.1±0.4 nm) than L-PAMPS, therefore, has a smaller size: 
charge ratio. Consequently, it could be predicted that L-PAMPS containing particles 
would have a lower zeta potential than B-PAMPS containing particles.  
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The L- and B-PAMPS macro-monomers were produced by RAFT polymerisation 
(protocol detailed in [221]). RAFT allows for the production of polymers with 
controlled chain lengths and controlled degrees of branching. It was for these 
reasons that RAFT was chosen as the synthesis method for PAMPS macro-
monomers. In future, it could be possible to finely control the particle shell size by 
altering the chain length or degree of branching of the PAMPS macro-monomer.  
 
 Protein release from OPHP functionalised core-shell particles 
 
Colloidally stable core-shell particles have been synthesised in a two-step batch 
emulsion process. These particles can be altered by differing cross-linking density 
and by varying cross-linking units. The inclusion of OPHP was to provide a 
negatively charged unit in the outer shell of the particle. OPHP has previously been 
identified as being able to bind and release VEGF for short periods of time [116]. 
This was expanded upon to act as a HS mimic for a variety of growth factors. VEGF165, 
PDGF-BB and EGF all showed different release profiles when released from 1:1 
OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles. 
It is thought that the particles not only electrostatically bind proteins, but also, exert 
a size exclusion effect on the protein bound within the outer shell. The particle shell 
can be thought of as a mesh-like structure. The size and density of the mesh can be 
altered by altering the degree of cross-linking or by altering the cross-linking units. 
(Varying the ratio of OPHP:EGDMA was the former variation and the inclusion of 
GMAC was the latter alteration). If a protein is large compared to the particle shell 
mesh size, it cannot bind within the particle shell. However, if the protein is small 
compared to the particle shell mesh size, it can bind within the particle shell, as the 
protein is able to pass though the polymer mesh. A protein bound and enclosed by 
the particle shell will have access to more electrostatic binding sites than a protein 
bound to the outer surface of the particle shell. Upon release, the protein would be 
move through the particle shell by diffusion and would be forced into contact with 
other electrostatic binding sites. Access to more electrostatic binding sites will hold 
the protein in the correct conformation for longer periods of time. If there is a large 
disparity in size between the protein and polymer mesh size (for example, a very 
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small protein in a large mesh), the effect of the sequential electrostatic binding may 
not be felt and would have little effect on the protein release profile. 
Figure 4.5 shows the release of VEGF from 1:3, 1:1 and 3:1 OPHP:EGDMA shell 
particles. The variation of the quantity of EGDMA could produce a particle shells 
with a differing mesh-like structure. Increasing the amount of EGDMA present in the 
particle shell could produce a looser mesh structure and decreasing the amount of 
EGDMA could produce a tighter, smaller mesh structure. DLS measurements (Figure 
4.1) shows increasing particle size with increasing quantity of EGDMA, which would 
be consistent with this theory. Figure 4.5 shows that increasing the quantity of OPHP 
(or negatively charges phosphate groups) in the shell did not result in more VEGF 
released from the particle shell.  
Figure 4.6 shows the release of VEGF from 4:1:3, 2:1:1 and 4:3:1 
OPHP:GMAC:EGDMA shell particles. The quantity of OPHP remained the same 
throughout the three materials, therefore, any variation on binding would be due to 
the particle shell structure. The ratio of OPHP: cross-linker was the same as that for 
1:1 OPHP:EGDMA. When deprotected, GMAC is more hydrophilic than EGDMA. It is 
thought that this could bind more water within the particle shell producing a 
swollen mesh-like structure. As previously discussed, Figure 4.2 shows an increase 
in particle size as more GMAC is incorporated into the polymer.  
1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA particles were chosen for further 
study because they showed a favourable release profile for the release of VEGF over 
72 hours. They also have comparable quantities of phosphate within the polymer 
shell, therefore, any variation in protein release is due to the particle structure. 
Figure 4.7, Figure 4.8 and Figure 4.9 show the release of VEGF, PDGF and EGF 
respectfully. For the release of VEGF and PDGF, 1:1 OPHP:EGDMA consistently 
showed less protein detected at each time point and a smaller burst release than 
2:1:1 OPHP:GMAC:EGDMA. 2:1:1 OPHP:GMAC:EGDMA particles show more VEGF 
and PDGF detection at each time point but also exhibits a larger burst release phase 
and earlier plateau region than 1:1 OPHP:EGDMA particles do. There was no 
significant difference between the release of EGF from either material.  
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The three proteins studies varied in size: VEGF 38.2 KDa, PDGF. 24.4 KDa and EGF 
6.3 KDa. It is hypothesised that the variation in protein size and the variation in 
particle shell structure would have an effect of the release profiles on said proteins. 
It can be assumed that all the proteins have a similar proficiency for electrostatically 
binding to negatively charged phosphate groups. This assumption is based on the 
number of arginine and lysing units in the protein backbone but, the conformational 
arrangement of these groups is not taken into consideration at this time. For VEGF 
to bind within the particle shell, the shell mesh size would have to be larger than for 
either PDGF or EGF to bind within the particle shell. Alternatively, for the particle 
shell mesh-size to have both an electrostatic binding effect and a size exclusion effect 
on EGF, the shell mesh-size would need to be smaller than for VEGF or PDGF binding.  
Figure 4.7, Figure 4.8 and Figure 4.9 show that  the larger protein (VEGF) has a 
slower release from the particles with the largest particle shell mesh size (2:1:1 
OPHP:GMAC:EGDMA). The medium sized protein (PDGF) has an initial burst release 
where we can assume the protein has been stabilised and released from the surface 
of the particles. Finally, the smallest protein (EGF) shows very little extra stability 
produced by the two different shells.  This could be because the particle shell mesh 
sizes are both large in comparison to the protein and not slowing the release of EGF 
by sequential binding to phosphate groups within the particle shell. 
Analysis of protein by ELISA is a sensitive analysis technique that is commonly used 
in research and diagnostics. However, it is not without problems. Some of these are 
address in the introduction chapter (alternative protein analysis techniques, page 
35). When protein is released from core-shell particles it is only detected with ELISA 
if the protein is still intact. Table 4-2, Table 4-3 and Table 4-4 show the initial protein 
uptake of VEGF, PDGF and EGF by 1:1 OPHP:EGDMA and 2:1:1 OPHP:GMAC:EGDMA 
particles. This data alone cannot be used to definitively determine the successful or 
unsuccessful protein uptake by a material. If the protein has been denatured or 
undergone any primary structure damage the ELISA may not detect the protein. This 
must always be kept in mind when analysing data from ELISA. However, there are 
complimentary techniques that can be adopted alongside ELISA. One possible 
option would be to use FTIR to detect any free peptide bonds. The presence of these 
would indicate that there have been breakage of the primary amino acid sequence. 
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If the amino acid primary structure is broken, it would therefore, be unlikely that all 
of the protein present in the sample is being detected. This technique would be quick 
to run and immediately give information on the state of the proteins present. 
However, practically this may prove difficult as the protein sample contains BSA and 
other biological molecules that may result in FTIR data not definitively coming from 
the protein of interest.  
The ability to release VEGF and PDGF over long periods of time would be greatly 
advantageous for wound healing. Table 1-1 and Table 1-2 give examples of other 
materials for release of VEGF and PDGF respectively. VEGF was released over 31 
days which is considerably longer than those studies of VEGF release from 
microparticles by Karal-Yilmaz et. al. and Patel et. al. [121, 124]. Biodegradable 
PLGA Gd-doped microspheres released VEGF for up to six week but a large burst 
release phase was not overcome [127]. Injectable PLG gels were able to release 
PDGF for 2-4 weeks and is a promising avenue for the stimulation of angiogenesis 
[130]. However, this system may not be as promising as first assumed when treating 
conditions, such as burns, where the material would not able to be injected. By 
looking at other GF release systems it is clear there is still a clinical need that has not 
been fully met.  
 
 Protein release from PAMPS functionalised core-shell particles 
 
Particles with a BMA core and either L-PAMPS or B-PAMPS shell can bind, stabilise 
and release a variety of growth factors over a period of 1-31 days. Negatively 
charged sulfonic acid groups present on PAMPS produce a HS mimic that can bind 
to arginine and lysine amino acids present in various proteins. The structure of the 
particle shell and size of protein have a profound effect on the release profile. 
As previously described, the particles are thought to not just electrostatically bind 
to the protein released, the shell architecture is thought to play an equally important 
role in the binding and release of proteins.  L-PAMPS could form a micelle like 
structure around the BMA core. The hydrophilic sulfonic acid groups would be 
mainly on the outside and the hydrophobic chain would surround the BMA centre. 
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These linear chains would be flexible and could accommodate proteins of varying 
sizes.  
B-PAMPS would produce a more rigid mesh structure around the BMA core. 
Although not cross-linked, the branching of the PAMPS would intertwine. To ease 
explanation, it is assumed the B-PAMPS shell is a rigid or semi rigid structure with 
holes or pores in the shell. In the case of B-PAMPS, hydrophilic sulfonic acid groups 
would be available on the surface of the particle and within the pores in the particle 
shell. If a protein is large compared to the B-PAMPS pore size, it cannot bind within 
the particle shell and would only bind on the particle surface. However, if the protein 
is small compared to the B-PAMPS pore size, it can bind within the particle shell, as 
the protein is able to pass into the polymer pores. Since it is assumed that in the B-
PAMPS shell, sulfonic acid groups are present throughout, a protein bound and 
enclosed by the particle shell will have access to more electrostatic binding sites 
than a protein bound to the outer surface of the particle shell. When the protein is 
release by diffusion, it would move through the pore in the B-PAMPS shell and be 
forced into contact with other electrostatic binding sites. This will slow release and 
prevent the protein from denaturing in the aqueous environment. As with 
previously described particles, if there is a large disparity in size between the 
protein and B-PAMPS pore size (for example, a very small protein in a large pore), 
the effect of the sequential electrostatic binding may not be felt and would have little 
effect on the protein release profile. 
Figure 4.10 and Figure 4.11 show there was a significant difference in the release of 
VEGF and PDGF when comparing linear and branched shells. As with OPHP 
functionalised materials, it was found that the quantity of negative electrostatic 
binding groups in the shell produced little difference in the protein release profile. 
L-PAMPS released VEGF in a linear fashion over 31 days. The release of VEGF from 
B-PAMPS began to slow after approximately 14 days. L-PAMPS released PDGF 
slowly over 31 days. There was no obvious burst release seen and no plateau region 
but only small amounts of protein was detected. B-PAMPS released PDGF in a close 
to linear fashion for 31 days. There was no significant difference between L- and B-
PAMPS with the release of EGF.  
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These release profiles could be explained by the architecture of the particle shell. L-
PAMPS shell is flexible and can move to accommodate different sized proteins. B-
PAMPS shell can be thought of as a rigid structure containing pores. VEGF was the 
largest protein investigated and the release from B-PAMPS was slow and eventually 
plateaued.  This could be because VEGF was too large to bind deep within the B-
PAMPS shell, whereas, the flexible chains on L-PAMPS could wrap around VEGF 
giving access to a greater number of electrostatic binding sites and resulting in a 
slow, linear release of protein. PDGF is smaller than VEGF, meaning it could fit within 
the pores created in the B-PAMPS shell. This would mean that the protein could 
interact with the shell in various places as PDGF is released, thereby, slowing the 
release of PDGF from a B-PAMPS shell. The smaller size of PDGF means that the 
flexible linear chains can move to accommodate the protein. However, there is only 
one negative sulfonic acid group per AMPS unit, therefore, a smaller protein will 
come into contact with less electrostatic binding sites than a larger protein. This 
would reduce the stabilisation of the protein and result in lower protein recovery 
when compared to B-PAMPS. Neither L-PAMPS nor B-PAMPS shells produced a 
sustained release of EGF. This could be due to EGFs small size. The protein may be 
too small to be affected by sequential electrostatic binding within the pores of the 
B-PAMPS shell. This would result in proteins being less stabile (and unable to be 
detected by ELISA) and release not being sustained over longer periods of time. The 
small size of EGF could also prevented it from binding sufficiently to L-PAMPS. As 
the L-PAMPS chains try to arrange themselves around the small protein, repulsion 
from the neighbouring negatively charged regions may be felt. This would result in 
little electrostatic binding occurring and L-PAMPS having little effect on the binding 
and release of EGF. 
The release of VEGF, PDGF and EGF from L- and B-PAMPS was similar to that of 1:1 
OPHP:EGDMA and  2:1:1 OPHP:GMAC:EGDMA particles. All release data displayed 
the importance of particle shell architecture. It can be assumed that the phosphate 
groups on OPHP and the sulfonic acid groups on PAMPS are acting as a HS mimic 
and are binding to the proteins via arginine and lysine amino acids. VEGF had the 
best protein recovery with all materials studied (1:1 OPHP:EGDMA, 69%; 2:1:1 
OPHP:GMAC:EGDMA, 99%; L-PAMPS, 95%; B-PAMPS, 54%). PDGF had varied 
protein recovery (1:1 OPHP:EGDMA 30%; 2:1:1 OPHP:GMAC:EGDMA 53%; L-
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PAMPS, 12%; B-PAMPS, 33%) and EGF had very poor protein recovery (1:1 
OPHP:EGDMA and  2:1:1 OPHP:GMAC:EGDMA, 1.5%; L-PAMPS, 1%; B-PAMPS, 
0.8%). As previously discussed, techniques complimentary to ELISA would be 
needed to determine why any remaining protein was not detected. From comparing 
all the core-shell particles studied, it is clear that different materials are better suited 
to releasing certain proteins.  
PAMPS stabilised emulsion polymers have not been previously used for release of 
VEGF, PDGF or EGF. However, work by Liekens et. al. and Garcia-Fernandez et. al. 
showed that sulfonic acid groups can bind growth factors from cell culture media 
[218, 219]. L- and B-PAMPS shell particles exhibited excellent protein uptake (Table 
4-5, Table 4-6 and Table 4-7) and it is reasonable to assume that there may be 
unprotected protein remaining bound to the sulfonic acid groups on the particle 
shell.  
 
 Analysis of NVP-co-DEGBAC hydrogels 
 
Different wounds needs different environments to promote healing. A wound must 
often be kept in a moist environment. This is to prevent any further cell death; 
promote cell replication and angiogenesis; and to help relieve pain to the patient 
[241]. However, skin can be damaged by continued exposure to incorrect water 
levels. This is known as maceration and refers to any damage caused to the skin by 
excessing water or bodily fluids. This can result in death of healthy tissue and an 
increased risk of infection [242]. It is for these reasons that it is important to monitor 
the water content of hydrogels produced for wound dressing systems.  
Table 4-8 shows the water content of PVP-co-DEGBAC control hydrogel and PVP-co-
DEGBAC gels containing L-PAMPS, B-PAMPS, 1:1 OPHP:EGDMA, 2:1:1 
OPHP:GMAC:EGDMA particles. The water content of the hydrogels containing 
embedded particles (86.12±2.26 – 88.68±0.9 %) is higher than the control gel 
(85.37±1.2 %). This would be expected as the all the particles contain hydrophilic 
groups, either in the form of negatively charged group, or hydrophilic cross-linking 
units. It could be possibly to control the water content of PVP-co-DEGBAC hydrogels 
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by altering the ratio of hydrophilic and hydrophobic units. Additional hydrophilic 
groups could increase the water content of a hydrogel and a reduction in hydrophilic 
units could decrease the water content. This would allow for the material to be 
tailored to the needs of a particular wound. However, the overall mechanical effects 
of altered water content must be taken into account. The resultant hydrogel must 
still be flexible, offer a barrier to bacterial colonisation and release growth factors 
over a useful time frame.   
To gain an understanding of how the particles were embedded in the hydrogel SEM 
images were taken. Figure 4.13 shows surface and edge images of the PVP-co-
DEGBAC control and particle embedded gels. Very little information could be gained 
from these images as the hydrogels must be dry prior to imaging. This resulted in 
the internal hydrogel structure collapsing. This can be seen by the characteristic 
wrinkled effect on the surface of the gel. Alternative imaging techniques will be 
discussed later.  
For a hydrogel to be used as a wound dressing it must be able to be sterilised. The 
PVP-co-DEGBAC hydrogels used were sterilised with a series of ethanol washing 
steps. This sterilised the materials but is time consuming and could be ineffectual 
for thicker materials, as it relies on the ethanol soaking throughout the hydrogel. 
Alternative sterilisation techniques could be heat treatment or irradiation. The 
effect of heat sterilisation would have to be investigated as it is possible that high 
temperatures needed for heat sterilisation may affect the structure of the hydrogel 
[263]. Studies on UV irradiation for sterilisation of hydrogels had limited success. I 
was found that UV irradiation did not mean cGMP standards for sterilisation of a 
biomaterial [264]. Gamma irradiation of NVP based materials have shown that it can 
be an effective method for sterilisation of hydrogels [265, 266]. However, gamma 
irradiation was shown to increase crosslinking in the polymer, which may results in 
differing performance, particularly water content [266].  Furthermore, in these 
particle embedded PVP-co-DEGBAC hydrogels the effect of any sterilisation 
treatment of the core-shell particles must also be addressed.   
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 Protein release from particles embedded in NVP-co-DEGBAC hydrogels 
 
A set of NVP-co-DEGBAC hydrogels containing embedded core-shell particles were 
synthesised. The hydrogels contained either 1:1 OPHP:EGDMA, 2:1:1 
OPHP:GMAC:EGDMA, L-PAMPS or B-PAMPS particles. Figure 4.14-4.16 show the 
release of VEGF, PDGF and EGF. They show that the hydrogels containing core-shell 
particles performed worse than the core-shell particles tested alone. However, the 
exception to this was hydrogels containing L-PAMPS and B-PAMPS particles 
releasing VEGF. These hydrogels performed equal to or better than the particles 
alone. The behaviour of these materials is still not understood. The structure of the 
L- and B-PAMPS shells may prevent the hydrogel material from penetrating the 
particle shell. This could allow the sulfonic acid groups on the PAMPS macro-
monomer to remain available for binding to proteins.  
Previous work by Gilmore et. al. used PVP-co-DEGBAC-co-AA hydrogels 
functionalised with tri-arginine (RRR) and heparin [248]. The release profile of 
VEGF was studied over 72 hours. Over the course of 72 hours, the best performing 
material released approximately 26% of the protein loaded. The cumulative release 
showed an initial burst phase and then released small portions of VEGF over the 
course of the study. When heparin functionalised material is compared to the 
particle embedded hydrogels, the particle embedded materials initially seem to 
perform better. L-PAMPS and B-PAMPS embedded particles both release a higher 
payload during the experimental time period. This would be desirable for a VEGF 
release system, as VEGF is needed in the initial stages of angiogenesis. More 
importantly, they are easier and cheaper to synthesise than producing a peptide 
functionalised material. The batch variance that is often found with natural 
materials (in this case heparin) can also  be eliminated.  
One method for increasing the performance of the particle embedded hydrogels 
could be to pre-load the core-shell particles with protein prior to embedding into 
the hydrogel. This is a method that is often used when releasing proteins or drugs 
from encapsulated particles (see Table 1-1and Table 1-2). This may prevent the bulk 
hydrogel material (NVP and DEGBAC) from blocking binding sites on the particles, 
resulting in the core-shell particles maintaining their protein release behaviour. 
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However, there is one main problem that a technique such as this faces. The 
hydrogels are cured by either UV photo-curing or heat curing. Obviously, heat curing 
is not an option with pre-loaded particles embedded into the gel structure. UV 
curing has potential but the gels are synthesised un-swollen with propan-2-ol as a 
solvent. This environment would not be accommodating to environmentally 
sensitive proteins, such as VEGF and PDGF.  For this to be successful, a different 
synthesis protocol for UV curing would have to be developed to allow the gels to be 
cured with water as a solvent.  
Although the quantity of protein released from the hydrogel can be estimated via 
ELISA, the binding site within the hydrogel is not known. It is assumed that the 
proteins bind to either the phosphoric acid or sulfonic acid sites on the embedded 
core-shell particles but this has not been confirmed. It is possible that there is 
protein non-specifically bound within the bulk hydrogel material. It is possible to 
radio label proteins prior to binding to the hydrogel material. An autoradiograph 
can then be produced of the hydrogel. This would show the spatial arrangement of 
the protein within the gel. If the protein was only bound to particles, you would 
expect to see high concentration clumps of radiolabelled protein within the gel. If 
there was non-specifically bound protein present, you would expect to see a 
consistent distribution throughout the hydrogel. This technique would also give 
information about the concentrations of protein bound and if there is any protein 
bound that cannot be detected by ELISA. A variety of peptide radio labels are 
available for binding to proteins, with new ones developed specifically for VEGF to 
assist with cancer diagnosis [267].  
 
 Analysis of acryloxyethyl thiocarbamoyl rhodamine B labelled particles 
 
Water stable fluorescent particles have been produced by incorporating 
acryloxyethyl thiocarbamoyl rhodamine B into the core and throughout the particle. 
A two-step batch emulsion system was used to produce particles with a polystyrene 
divinyl benzene acryloxyethyl thiocarbamoyl rhodamine B core and 1:1 
OPHP:EGDMA or 2:1:1 OPHP:GMAC:EGDMA shell. By using this two-step system it 
was hypothesised that the fluorescent label was mainly confined to the core of the 
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particle. Acryloxyethyl thiocarbamoyl rhodamine B has large hydrophobic areas 
that could preferentially arrange themselves into the hydrophobic PS-co-DVB core. 
However, acryloxyethyl thiocarbamoyl rhodamine B is still partially water soluble 
so some could remain in the aqueous phase during the polymerisation of the particle 
core. If there was fluorescent label in the aqueous phase upon addition of the shell 
monomers, it could be assumed that some label will also be incorporated into the 
particle shell. Table 4-9 and Table 4-10 show particle size, zeta potential and sold 
content analysis for fluorescently labelled 1:1 OPHP:EGDMA and 2:1:1 
OPHP:GMAC:EGDMA shell particles. Zeta potential measurements indicate the 
particles are colloidally stable and have a negative surface charge. This supports the 
theory that the fluorescent label (which contains a positive charge) is not within the 
shell in large quantities. The PS-co-DVB core is larger than that shown in Figure 4.1, 
which again indicates that the fluorescent label is polymerised within the core.  
A single step batch emulsion system was used to synthesis particles containing 
acryloxyethyl thiocarbamoyl rhodamine B in to BMA core with L-PAMPS or B-
PAMPS shell. Due to the method of production, it was impossible to definitively 
determine if the label would be contained solely in either the core or shell. Table 4-9 
shows that L- and B-PAMPS shell materials are colloidally stable and the 
incorporation of the fluorescent label is not exerting a detrimental effect on the 
stability of the particles.   
It was found that the equivalent to 1g PAMPS was not enough to act as a surfactant 
for the polymerisation of BMA and acryloxyethyl thiocarbamoyl rhodamine B. When 
the quantity of PAMPS was increased to the equivalent of 4g PAMPS, the macro-
monomer was a sufficient surfactant for the polymerisation. To fully understand 
why this occurs a full investigation into the kinetics of the reaction would need to be 
completed, as described by Platt et. al. [221].  
All particles labelled with acryloxyethyl thiocarbamoyl rhodamine B were instable 
in salt solutions. This is a known feature of latexes produced by emulsion 
polymerisation. However, the labelled particles were considerably less stable than 
their none labelled equivalents. This may be due to the positive charge present on 
the acryloxyethyl thiocarbamoyl rhodamine B label. One way of overcoming 
problems associated with salt instability would be to embed the labelled particles 
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into PVP-co-DEGBAC hydrogels, as previously described for none labelled particles. 
This would hold the particles in place and prevent them from aggregating when 
places in PBS or cell culture media. These materials would have the same problems 
associated with sterilisation as previously discussed in section 5.6. Although 
embedding the fluorescently labelled particles in the hydrogel would prevent 
aggregation in PBS and cell culture media, it would not allow for tracking of the cells 
in vivo. This would be useful if the materials were tested in animal models. 
 
 Protein degradation and analysis by alternative techniques 
 
Analysis of denatured and non-denatured proteins by electrophoresis showed a 
small difference between the two samples. Some peaks were confirmed by mass 
spectrometry however this was not as successful at determining protein stability as 
electrophoresis.  Release of VEGF from OPHP:EGDMA, OPHP:GMAC:EGDMA, L-
PAMPS and B-PAMPS coated core-shell particles show some noticeable difference 
between the stability of the protein. A comparative release from heparin proved 
unsuccessful. There is a clean need for complimentary protein analysis techniques 
to be used alongside ELISA. Alternative protein detection techniques have been 
heavily debated throughout and will be further addressed in the future work 
section.  
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6 Conclusions 
This project has produced a set of materials that are candidates for future inclusion 
in wound dressings. All materials produced where easy to synthesis, have the 
potential for scale up, and do not require expensive peptides or ECM components to 
release pro-angiogenic growth factors. The binding of protein to particles (or 
hydrogel) was via negatively charged groups within the particle shell. It was 
hypothesised that these groups were acting as a HS mimic, thereby, stabilising the 
protein in the aqueous environment.  
The conclusions are as follows: 
 Particles containing OPHP were reproducible and gave acceptable batch 
variation when comparing particle size and zeta potential measurements.  
 The inclusion of GMAC made the particle size significantly larger after 
deprotection.  
 The variation of shell composition had an effect on the release of VEGF and 
PDGF but no significant effect on EGF release.  
 Varying the quantity of PAMPS in the particle shell showed no significant 
difference in the release of protein but varying shell structure showed a 
significant difference in release of protein.  
 PAMPS particles could release VEGF and PDGF over 31 days but there was 
little release of EGF.  
 OPHP and PAMPS functionalised particles can be embedded into NVP-co-
DEGBAC hydrogels.  
 When embedded, most particles showed little functionality. The exception to 
this was L- and B-PAMPS, which release VEGF over 72 hours.  
 The L- and B-PAMPS particles embedded in NVP-co-DEGBAC performed 
comparably to previously studies heparin functionalised materials. 
 OPHP and PAMPS functionalised materials labelled with acryloxyethyl 
thiocarbamoyl rhodamine B produced latex particles with the fluorescent 
label incorporated, however, the particles aggregated over time.  
 Alternative protein analysis techniques did not prove as successful as ELISA.  
 
 
 
102 
 
  
 
 
103 
 
7 Future Work 
The materials produced are a promising choice for potential future uses for wound 
dressings. However, the full capabilities of the materials have not been explored and 
there are still many questions to be answered. The main area of future work would 
need to focus on is confirming the size exclusion effect occurring within the particle 
shells. This could be done by expanding the number of proteins under investigation. 
The three proteins chosen (VEGF, PDGF and EGF) where done because of their size 
and also the biochemical and physiological relevance to angiogenesis during wound 
healing. Other potential protein release candidates would either have to bind to the 
ECM via heparin or contain areas with a high concentration of arginine and lysine 
units. Useful proteins to investigate could include: various forms of FGF (FGF-acidic, 
16.8kDa, FHF-basic, 16.4-17.2kDa), PlGF (29.7-45.7kDa) and HB-EGF (9.7kDa). 
There are several reasons this work has not been carried out to date. The first is that 
the range of proteins studied was deemed sufficient for giving an overview of the 
size limitations of the material. Rather than studying a wider variety of protein sizes, 
time was spent on finding out other limitations of the core-shell particles, such as 
embedding in hydrogels and the potential for inclusion of fluorescent labels for 
tracking movement of particles.  
One way of determining the sensitivity of the size exclusion effect is to alter the 
monomer units. Only one phosphate based monomer has been included in this work. 
The size of the particle shell was altered by changing the phosphate unit to 
crosslinker ratio. By including a large crosslinking unit the shell size was able to be 
substantially altered. However, it could be possible to finely tune the shell by 
changing the chain length of the phosphate monomer. This along with altering 
crosslinking units would give a system that has the potential to be finely tuned to 
release a particular protein at a desired time frame. By doing this the release plateau 
could be eliminated.  
Particles containing either L-PAMPS or B-PAMPS showed that shell architecture also 
has an effect on the release of proteins. This could be investigated further by altering 
the degree of branching of the PAMPS to produce a series of materials with various 
degrees of branching.  The degree of branching of the PAMPS can be altered by 
changing the ratio of monomer to chain transfer agent. If more chain transfer agent 
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is used, the degree of branching increases. The production of PAMPS with varying 
degrees of branching has been investigated within the research group during an 
undergraduate masters project by John De Crescenzo. The PAMPS was used during 
emulsion polymerisation but PAMPS with high degrees of branching had insufficient 
surfactant-like properties which lead to unstable latex formation. If this work was 
re-visited it could be possible to produce a set of particles with different sized pores 
in the particle shell. This would align with the theory that shell architecture also 
plays an important role in protein binding to be tested.  
Embedding the particles in a gel would be essential for this system to be used as a 
wound dressing. The gel not only allows for easier handling but also can keep the 
wound moist and reduce bacterial colonisation [241]. To produce an ideal wound 
dressing the specific conditions created by the hydrogel would need to be 
investigated. These include: water content, oxygen and air flow and whether a 
second layer would need to be added to the hydrogel. To produce a usable wound 
dressing a collaboration with clinicians and potentially industry would be needed. 
This would give access to applicable expertise and industrially relevant research 
and development practices. Tissue and bacteria culture would also have to be 
undertaken to ensure the dressing does not allow bacteria to cross though the 
dressing and skin is still able to grow in close proximity to the material. PVP is 
frequently used as a material for wound dressing however crosslinking unit ratios 
and solvent ratios may need to be altered to produce a system that is more suited to 
particular types of wounds [243]. 
The manner in which the particles are set in the hydrogels also needs to be 
determined. It was found that upon drying in preparation for SEM the hydrogels 
collapse slightly resulting in a creased surface to the gel. Due to this is was difficult 
to gain an insight into how the particles sat within the gel. However, imaging using 
an alternative SEM technique may prevent this. Environmental SEM would allow for 
the hydrogels to remain semi-swollen. Cryo-TEM would be able to give a cross 
section of the hydrogel with the embedded particles. Since the sample is frozen, 
there should not be problems associated with the collapse of the material upon 
drying as with standard SEM techniques.  
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The release data from the hydrogels shows potential specificity for particular 
proteins.  This would need to be further investigated to determine if the hydrogel 
system can be used to specifically select proteins from a mixed solution. This could 
be done simply by soaking the hydrogel in a protein solution, as described in section 
3.7.2 (page 52). The released proteins could be analysed by ELISA as previously 
described. If the hydrogel system was specifically selecting one protein over others 
there should be a significantly higher quantity of one protein detected. Obviously, 
any potential ELISA cross-reactivity would have to be investigated prior and any 
proteins that show cross-reactivity could not be used. If the hydrogel system is 
capable of specifically selecting a particular protein from a mixed solution and 
release the protein in a biologically viable state, it could have a potential application 
in protein separation and purification.  
The inclusion of rhodamine B into particles resulted in a pink latex that fluoresces 
within the red region of the spectrum. Although rhodamine B could be successfully 
incorporated into the polymer, the level of label incorporation was low. The quantity 
of rhodamine B incorporated into the polymer was not determined in the above 
work. One way this could be done is by monitoring the quantity of label washed out 
during dialysis. It can be assumed that if the label diffuses out during dialysis, it is 
not bound to the polymer chains. At each stage during dialysis (at each solvent 
change), a sample of the dialysis solution could be taken and analysed by UV-visible 
spectroscopy. This allows for the quantity of rhodamine B to be monitored over 
time. However, one problem associated with this method is photo-degradation of 
rhodamine B over time [268]. This could lead to lower rhodamine B levels being 
recorded.  
The main problem associated with the particles containing rhodamine B is 
aggregation over time. This was concluded to be due to salt instability mainly from 
the positively charged unit on free rhodamine B. This was partially reduced by 
immediate dialysis after polymerisation has finished. However, if these were to be 
synthesised on a larger scale, the aggregation would need to be reduced as much as 
possible. One way this may be achieved, is to use a different label with no charged 
regions. There are a plethora of fluorescent labels that could be chosen, however 
there are a few criteria they must adhere to. First, is they must contain a region that 
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could be polymerised into the particles. This is usually a double bond in the form of 
an acrylate or methacrylate group. The second criteria is that the label should not 
contain charged regions because this has been shown to cause aggregation if any 
free label is left in solution. Finally, the label cannot be too large, as this could 
potentially disrupt the core-shell structure of the particles. Any change in core-shell 
structure could be monitored by TEM.  
A clear, definitive ideal time frame for protein release must be determined. This 
would need to be done for each protein released from the material. During healing, 
each protein will have a different role that would be needed at different timepoints. 
However, the exact role of each protein involved in healing has not been fully 
determined and the extent of their importance has not been realised. Until this 
information is available, it would be difficult to have a perfect system that could 
release all the proteins needed at the ideal timepoints. 
The practicalities of protein loading must also be addressed. In an ideal situation, 
the wound dressing would not need to be pre-loaded with protein. It would be put 
on a recent wound and could capture, stabilise and slowly release the vast mixture 
of proteins that are produced by the body after injury. In reality, these proteins are 
released and quickly degrade in the body, resulting in the majority of the proteins 
not interacting with cells. This type of dressing would need to be able to selectively 
capture proteins of interest and not be damaged or fouled by other biomolecules 
and cells that are present in a wound. Obviously, a system such as this would need 
many years of development and in vitro and in vivo testing. When determining the 
suitability of the materials for a wound dressing, the long term degradation must be 
looked at. This would determine if the material undergoes detrimental biofouling 
and how often the dressing would need to be changed. An incubator at 37oC could 
be used for determining any chemical degradation that occurs. TEM would be a good 
tool to use to visualise any change in structure with time. Protein release studies 
should be done at various time points to see how older materials interact with 
proteins. To investigate how the material acts in the body, animal models would 
have to be used. In vivo studies would need to be completed for the materials to be 
deemed suitable as a wound dressing.  
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The bioactivity of any protein released must be determined. All of the techniques 
previously discussed, including gold standard protocols, have limitations associated 
with them. Matrigel assays are commonly used for assessing endothelial cell growth 
in response to a pro-angiogenic stimuli [139, 149-151]. It could be used to assess 
endothelial cell response (via cell replication) to supernatant from particles 
containing released protein. A matrigel assay could also be used to assess cell 
movement towards the source of growth factors by using particle embedded 
hydrogels. However, as previously discussed, matrigel has problems with giving 
false positive results [148]. A matrigel assay would be a good starting point for 
assessing bioactivity.  
After an in vitro model had been used to assess bioactivity an in vivo model must be 
performed.  In vivo work is expensive, time consuming and often requires ethical 
approval. The gold standard for assessing angiogenesis in vivo is the ischemic hind 
limb model. Initially, it is possible to reduce costs and ethics approval by using 
zebrafish as a candidate for in vivo study. However, this does not allow for long term 
(greater than 4 days) release or implantation studies.  
An in vitro or/and an in vivo wound healing model would also be appropriate to use.  
In vitro models mimic the healing process using cells from the dermis and epidermis 
by culturing on a hydrogel like material [269]. Other cells, such as macrophages, can 
be added to mimic the extracellular environment. In vivo models allow for more 
complex wounds to be modelled, such as, diabetic wounds, chronic and acute 
wounds, and wounds in aging populations. Porcine models are the ideal candidate 
for human wound healing. However, this model is not as popular as small animal 
models, such as rodents, due to the animal size and husbandry requirements. Rather 
than a porcine model, the mouse dorsal trunk skin model is the most popular for in 
vivo wound healing [270].  
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8 Supplier Information 
Chemical 
Suppliers 
Cell Culture 
Suppliers 
Gel 
Electrophoresis 
Suppliers 
ELISA kit 
Suppliers 
Equipment 
Suppliers 
 
Sigma-Aldrich 
Company Ltd 
The Old Brickyard  
New Road 
Gillingham  
Dorset  
SP8 4XT  
 
Merck Millipore 
Suite 3 & 5, Building 
6, 
Croxley Green 
Business Park  
Watford  
Hertfordshire  
WD18 8YH  
 
Fisher Scientific UK 
Ltd  
Bishop Meadow 
Road  
Loughborough  
LE11 5RG 
Alfa Aesar Shore 
Road Port Heysham 
Industrial Park 
Heysham  
Lancashire  LA3 2XY 
Polysciences 
Europe 
Handelsstasse 3 D-
69214 Eppleheim 
Germany 
Thermo Fisher 
Scientific 
Stafford House 
1 Boundary Park 
Boundary Way  
Hemel Hempstead 
Hertfordshire HP2 
7GE 
 
Bio-Rad 
Laboratories Ltd 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire 
HP2 7DX 
 
 
 
PromoCell 
Sickingenstr 63/65 
69126 Heidelberg 
Germany 
 
VWR  
Hunter Boulevard 
Magna Park 
Lutterworth 
Leicestershire 
LE17 4XN 
 
 
Bio-Rad 
Laboratories Ltd 
Bio-Rad House 
Maxted Road 
Hemel Hempstead 
Hertfordshire 
HP2 7DX 
 
 
R&D Systems  
19 Barton Lane 
Abingdon Science 
Park 
Abingdon, OX14 
3NB 
 
Peprotech 
PeproTech House 
29 Margravine Road 
London  
W6 8LL 
 
 
 
Spectrum 
Laboratories Inc. 
P.O. Box 3262 
4800 DG Breda 
The Netherlands 
Brookhaven 
Instruments 
Corporation 750 Blue 
Point Road      Holtsville          
NY 11742 
FEI  5350 NE Dawson 
Creek Drive Hillsboro  
Oregon        97124              
USA 
Dynex Technologies 
GmbH  
Heerweg 15D 
73770 Denkendorf 
Germany 
Perkin Elmer Chalfont 
Road Seer 
Green Buckinghamshire 
HP9 2FX 
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9 Appendix 
 
Calibration graphs for VEGF165, PDGF-BB and EGF. The concentration of released 
protein can be determined using these graphs.  
0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0 2 5 0 0
0 .0
0 .5
1 .0
1 .5
V E G F  c o n c e n t r a t io n  ( p g / m l)
O
p
ti
c
a
l 
d
e
n
s
it
y
 
Figure 9.1 Example calibration graph for VEGF ELISA. For each 96 well ELISA plate ran an optical density to 
concentration calibration must be performed. 
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Figure 9.2 Example calibration graph for PDGF ELISA. For each 96 well ELISA plate ran an optical density to 
concentration calibration must be performed. 
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Figure 9.3 Example calibration graph for EGF ELISA. For each 96 well ELISA plate ran an optical density to 
concentration calibration must be performed. 
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